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Cardiovascular disease (CVD) is the leading cause of death in the world 
accounting for 17.3 million deaths annually. Transcatheter aortic valve replacement 
(TAVR) was developed 13 years ago to treat people suffering from one of the most 
common manifestations of CVD, valve disease. While preliminary research has 
indicated that physiological benefits of TAVR are favorable, psychosocial benefits and 
psychosocial predictors for physical and psychological outcomes have received less 
attention. In the current study, TAVR patients (N = 34) were queried on a number of 
biopsychosocial factors at baseline and three months post-op. Results revealed 
substantial improvement in both general and disease specific QOL post-TAVR as 
measured by the SF-12 PCS (z = -2.84, p = .004, r = .69) and KCCQ (z = -3.36, p = 
.001, r = .84). There was also a decrease in anxiety as measured by the HADS (z = -
2.47, p = .014, r = .58) and dyspnea as measured by selected items of the UCSD-
SOBQ (z = -3.01, p = .003, r = .71). Biopsychosocial factors that were most strongly 
associated with the greatest improvement in disease specific QOL post-TAVR were low 
baseline scores on the KCCQ (r = -.811, p < .01), low levels of physical activity (r = -
.625, p < .05), and worse dyspnea (r = .620, p < .05). Contrary to hypothesis, there was 
	  no significant association between baseline levels of positive expectations, satisfaction 
with life, or psychological distress, with post-op QOL improvement. Overall, results 
suggest that patients may experience meaningful gains in QOL post-TAVR and, in fact, 
those patients who report the worst biopsychosocial health at baseline may likely 
experience the most substantial QOL improvements. 
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CHAPTER 1: INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death in the world 
accounting for 17.3 million deaths annually, with an expected increase to 23.3 million by 
2030 (World Health Organization, 2011). CVD manifests in a variety of ways including 
myocardial infarction, stroke, heart failure, arrhythmia, and heart valve disease. Valve 
disease has traditionally been treated with surgical aortic valve replacement (SAVR), an 
invasive, open-heart procedure with high mortality risk for many elderly patients 
(Brennan et al., 2012). Transcatheter aortic valve replacement (TAVR) was developed 
13 years ago as an alternative procedure with an important benefit of much lower 
mortality risk (Cribier et al., 2002). The quality of life (QOL) benefits of TAVR have been 
established as desirable, but psychosocial benefits and predictors for physical and 
psychological functioning outcomes have not been examined. The current 
biopsychosocial investigation gathered and analyzed information from patients 
undergoing TAVR by using a self-report survey. The first aim of the study was to 
describe the characteristics of a population of TAVR patients who were contraindicated 
for SAVR, across the following areas: demographics, physical activity, medication 
adherence, QOL, anxiety, depression, life satisfaction, positive health expectations, 
dyspnea, and will-to-live. The second aim was to examine changes in TAVR patients 
from pre-surgery baseline to 3-months post-surgery in several of the same areas 
including: physical activity, QOL, anxiety, depression, dyspnea, and will-to-live. The 
third aim was to investigate possible predictors of change in QOL in TAVR. Predictors 
that were analyzed independently were baseline levels of QOL, anxiety, depression, 
satisfaction with life, positive health expectations, dyspnea, and will-to-live.  
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The current study provides information that will educate valve patients, health 
care providers, and family members of the potential benefits of TAVR versus the unique 
risks. It is also hoped that this information will help patients reap the full benefit of TAVR 
by increasing their knowledge and encouraging them to pursue personal change to 
reduce risk and improve broad health outcomes.  
	  CHAPTER II: LITERATURE REVIEW 
Cardiovascular Disease 
Cardiovascular disease (CVD) is a broad term that includes all diseases of the 
heart and blood vessels that collectively represent a worldwide epidemic. Not only is 
CVD the leading cause of death in the world (WHO, 2011), it is also the leading cause 
of death in the United States with approximately 600,000 Americans dying of CVD 
annually (Roger et al., 2011). In terms of financial cost, CVD accounts for expenditures 
of $108.9 billion annually in the US alone (Heindenrich et al., 2011), an amount that is 
increasing annually (Kochanek, Xu, Murphy, Miniño, & Kung, 2009; WHO, 2011).  
Heart Valve Disease 
About 5 million Americans are diagnosed with valve disease each year 
(American Heart Association, 2013) with the disease affecting 25% of people over 65 
and 48% of those over 84 (Stewart et al., 1997). Heart valves function by opening and 
closing with each heartbeat to properly direct blood flow. Diagnosis of valve disease is 
made when one of the four valves in the heart (tricuspid, pulmonary, mitral, and aortic) 
ceases to function properly. Aortic stenosis is the most frequently diagnosed valve 
disease among people over the age of 75 in the Western World with a prevalence of 
2.5% at 75 years of age, and 8.1% at age 85 (Nkomo et al., 2006). Aortic stenosis is a 
condition in which the valve between the left ventricle and the aorta narrows, thus 
obstructing blood flow onward to the rest of the body (Bonow et al., 2008). This 
condition demands that the heart regularly pump harder, weakening the heart muscle, 
and leading to symptoms such as angina, fatigue, shortness of breath, heart 
palpitations, heart murmur, and dizziness. Common causes of aortic stenosis include 
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congenital heart defects, calcium buildup on the valve, and rheumatic fever, and if 
unresolved, these conditions may lead to heart failure (Bonow et al., 2008; Goncalves et 
al., 2013).  Risk factors include old age, personal history of rheumatic fever, and family 
history of congenital aortic valve defects. Symptomatic aortic stenosis is responsible for 
problems that range in severity from restrictions in normal daily living to serious 
disability and reduced life expectancy (Bouma et al., 1999). Unfortunately, aortic valve 
stenosis is not considered a preventable condition.  
Traditionally, surgical aortic valve replacement (SAVR) has been the best 
treatment option for severe aortic stenosis. SAVR is an invasive procedure that requires 
making a 6-8 inch incision along the center of the sternum in order to gain access to the 
heart and aortic valve, and then repairing or replacing the valve depending on condition 
(Otto & Bonow, 2007). After valve replacement, hospital stays are typically 5-10 days 
followed by a 6-8 week recovery period. Studies of SAVR have shown improvements in 
QOL among elderly patients (>80) comparable to that of younger patients (Heijmeriks, 
Pourrier, Dassen, Prenger, & Wellens, 1999; Olsson, Janfjäll, Orth-Gomér, Undén, & 
Rosenqvist, 1996; Sedrakyan et al., 2003). However, SAVR is also associated with 
higher mortality rates in elderly populations. Brennan et al. (2012) examined data from a 
large sample of valve patients (N = 145,911) and found that the one-year mortality rate 
of low-risk, younger SAVR patients (< 70) was significantly better than in older patients 
(> 80) (5.7% vs.10.8%, p < 0.0001). Because of co-morbidities, surgical risk, or short life 
expectancy, almost a third of patients >75 are not candidates for traditional surgery 
(Iung et al., 2003).   
5	  
Transcatheter Aortic Valve Replacement (TAVR) 
Many frail patients are unable to undergo SAVR due to surgical risk (Cribier et 
al., 2002) and TAVR has emerged as a viable alternative. TAVR involves displacing and 
functionally replacing the patient’s native valve with a bioprosthetic valve that is 
delivered by a transvenous catheter, rather than through invasive, open-heart surgery.  
The two most common methods of delivery are via the femoral artery (transfemoral 
placement) or the left ventricular apex (transapical placement) (Smith et al., 2011). 
Other less common methods of valve delivery are subclavian, transaortic, and 
transcarotid implantation (Tang et al., 2013). The first human percutaneous 
transcatheter implantation of an aortic valve prosthesis was performed in 2002 (Cribier 
et al., 2002) and by 2008 about 1000 valve replacements had been completed 
worldwide (Vahanian et al., 2008). The number of TAVR procedures has increased 
dramatically in recent years and by 2013 over 50,000 had been completed (Tang et el., 
2013). 
Surgical Outcomes of TAVR vs. SAVR and Standard Therapy 
One of the first large studies of TAVR (N = 699) was the Placement of Aortic 
Transcatheter Valves (PARTNER) trial (Smith et al., 2011).  PARTNER sought to 
determine the safety and effectiveness of TAVR in high risk, symptomatic patients with 
severe aortic stenosis. Patients were recruited from 22 centers in the United States, 2 
centers in Canada, and 1 center in Germany. Smith and colleagues compared high-risk 
patients randomized to undergo SAVR or TAVR. At 30 days post-op, the all-cause 
mortality rate for TAVR patients was approximately half that of the SAVR group (3.4% 
vs. 6.5%, p = 0.07). The TAVR group also had less frequent major bleeding (9.3% vs. 
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19.5%, p < 0.001), less frequent new-onset atrial fibrillation (8.6% vs. 16.0%, p = 0.006), 
and greater New York Heart Association (NYHA) Class III or IV cardiac symptom 
improvement (p < 0.001). NYHA is the most commonly used classification system for 
describing patient symptoms of heart failure (AHA, 2013) (see Table 1).  
Table 1  
NYHA Functional Classification (AHA, 2013) 
Class Functional Capacity: How a patient with cardiac disease feels during physical activity 
I 
Patients with cardiac disease but resulting in no limitation of physical activity. 
Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or 
anginal pain. 
II 
Patients with cardiac disease resulting in slight limitation of physical activity. 
They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnea or anginal pain. 
III 
Patients with cardiac disease resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnea or anginal pain. 
IV 
Patients with cardiac disease resulting in inability to carry on any physical activity 
without discomfort. Symptoms of heart failure or the anginal syndrome may be 
present even at rest. If any physical activity is undertaken, discomfort increases. 
Additionally, TAVR patients had shorter stays in intensive care (3 vs. 5 days, p < 
0.001), as well as in overall hospital stay (8 vs. 12 days, p < 0.001). However, TAVR 
patients were more likely to have a major stroke (3.8% vs. 2.1%, p = 0.20) or major 
vascular complications (11.0% vs. 3.2%, p = 0.001). All-cause mortality differences 
between TAVR and SAVR patients were relatively equal at one year (24.2% vs. 26.8%, 
p = 0.44), while rates of major stroke continued to be greater for the TAVR group (5.1% 
vs. 2.4%, p = 0.07). There were no significant differences in symptom improvements at 
one year. Overall, these results indicated that while one-year mortality rates in both 
procedures were roughly equivalent, specific morbidity risks varied based on procedure. 
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A subsequent PARTNER trial was conducted to compare TAVR with standard 
therapy (e.g., balloon aortic valvuloplasty) in high-risk patients with severe aortic 
stenosis (Leon et al., 2010). Leon and associates reported on patients (N = 358) 
unsuited for SAVR, who had been randomized to TAVR or standard therapy. At 30 
days, TAVR patients experienced greater incidence of all-cause mortality (5.0% vs. 
2.8%, p = 0.41), major stroke  (5.0% vs. 1.1%, p = 0.06), and major vascular 
complications (16.2% vs. 1.1%, p < 0.001). TAVR patients also experienced reduced 
rate of NYHA Class III or IV cardiac symptoms (p < 0.001). At one year, however, all-
cause mortality in TAVR patients was much improved compared to standard therapy 
(30.7% vs. 50.7%, p < 0.001) as was rate of cardiac symptoms (25.2% vs. 58.0%, p < 
0.001) and re-hospitalization (22.3% vs. 44.1%, p < 0.001). Rates of stroke (10.6% vs. 
4.5%, p < 0.04) and major bleeding (22.3 vs. 11.2%, p = 0.007) were higher in TAVR 
patients. These results indicate that while TAVR resulted in worse outcomes 
immediately following the procedure, it was superior to standard therapy in reducing the 
rate of mortality and re-hospitalization at one year, even in light of higher specific, acute 
procedural risks. At two years, results revealed that TAVR patients had decreased rates 
of mortality (43.3% vs. 68.0%, p < 0.001), death due to all cardiac causes (31.0% vs. 
62.4%, p < 0.001), lower re-hospitalization rates (35.0% vs. 72.5%, p < 0.001) and 
fewer NYHA class III or IV symptoms (16.8% vs. 57.5%, p < 0.001) (Makker et al., 
2012). However, there continued to be higher rates of stroke (13.8% vs. 5.5%, p = 0.01) 
and major bleeding (28.9% vs. 20.1%, p < 0.09).  These results indicate that while the 
mortality benefit to TAVR over standard therapy is markedly better, there continues to 
be higher procedural risks for morbidity outcomes.  
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While some of the differences noted above from the PARTNER trials fall short of 
reaching statistical significance, they establish trends concerning the relative differences 
between TAVR and other medical or surgical procedures used to address aortic 
stenosis. Similar results have been found in non-PARTNER studies. 
Genereux and associates (2012) conducted a meta-analysis of outcomes of 
3519 TAVR patients from 16 studies completed between January 1, 2011 and 
December 10, 2011. Estimated mean 30-day and 1-year mortality rates were 7.8% 
(range 1.7–14.3%) and 22.1% (15.3–30.7%) respectively, and rate of major stroke was 
3.2% (0.8–9.0%). Major bleeding rate was 15.6% (7.0% - 25.9%) and vascular 
complications rate was 11.9% (5.0–23.3%).  
Patients who have undergone TAVR commonly have ongoing issues including: 
paravalvular leak, heart block, stroke, vascular complications, atrial fibrillation, 
concurrent coronary artery disease (CAD), LV dysfunction, prosthesis-patient mismatch, 
and problematic heart valve structural integrity and durability (Tang et al., 2013). 
Paravalvular leak is a side effect of the inability to ensure that the surface of the heart 
where the valve will be implanted is free of irregular surfaces. Thus, the seal between 
the heart surface and the valve is sometimes inadequate. Heart block (disruption of the 
heart’s electrical system) may possibly be exacerbated by the pressure of the valve on 
the His bundle or by other effects of the procedure that are yet not fully understood. 
These complications are carefully attended to by medical teams but are often 
irreversible.  
With regard to the financial cost, the total one-year cost of TAVR is 
approximately $67,000 while the one-year cost of SAVR is approximately $53,000 
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(Osnabrugge et al., 2013). The increased expense of TAVR is primarily due to higher 
procedural costs, specifically operating room use and materials. While the expense of 
TAVR exceeds that of SAVR, for inoperable patients Makker et al. (2012) noted that 
TAVR was cost-effective due to the reduced rehospitalization rates compared to 
standard therapy (e.g., balloon aortic valvuloplasty).  
Research Guidelines for TAVR 
Because of the recent emergence of the TAVR procedure, empirical research is 
needed to determine guidelines for patient selection beyond clinical judgment. Vahanian 
et al. (2008) recommended four steps of patient selection: 1) confirmation of the severity 
of aortic stenosis, 2) evaluation of symptoms, 3) analysis of the risk of surgery and 
evaluation of life expectancy and quality of life, and 4) assessment of the feasibility and 
exclusion of contraindications for TAVR. Vahanian et al. also recommended that QOL 
data be captured using standardized metrics, and that comparison groups should 
include patients who received SAVR.  
The Valve Academic Research Consortium (VARC-1), consisting of international 
experts in TAVR, was organized in 2009. VARC-1 met twice that year to define and 
establish appropriate clinical endpoints for TAVR in order to standardize clinical 
research (Leon et al., 2011). While the endpoints defined by  VARC-1 were primarily 
physiological in nature, they also noted the value of assessing clinical benefit endpoints. 
The use of the NYHA ratings was offered as one acceptable way to rate the clinical 
benefits of TAVR as they concern functional status. VARC-1 also suggested the use of 
the Kansas City Cardiomyopathy Questionnaire (KCCQ) to assess health-related QOL. 
The KCCQ is a 23-item measure commonly used to evaluate the health status of heart 
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failure patients (Creber, Polomano, Farrar, & Riegel, 2012). The five domains 
addressed by the KCCQ are:  symptoms, physical limitation, social limitation, self-
efficacy, and quality of life with higher scores indicating fewer symptoms and better 
QOL (Green, Porter, Bresnahan, & Spertus, 2000). The importance of assessing frailty 
as a clinical endpoint was also articulated. While no fixed method of evaluating frailty 
was established, VARC-1 did articulate the patient characteristics of mobility, strength, 
endurance, activities of daily living, cognitive impairment, and nutritional status as 
important criteria of frailty.  
Recommended VARC guidelines were further revised and published in 2012 
(Kappetein et al., 2012) (VARC-2). VARC-2 noted that improvements needed to be 
made in current predictive models for operative mortality in TAVR patients. Risk scoring 
commonly used to stratify patients has been done using the Society of Thoracic 
Surgeon (STS) risk score and the logistic EuroSCORE (EuroSCORE) with the STS 
having been found to be more accurate. The STS predicts risk of mortality in patients 
considered for cardiac surgery (Ad, Barnett, & Speir, 2007) and is calculated using an 
algorithm considering over 40 clinical parameters including patient demographics and 
various risk factors such as height/weight, diabetes, renal failure, hypertension, chronic 
lung disease, peripheral arterial disease, cerebrovascular disease, previous cardiac 
interventions, preoperative cardiac status, ejection fraction, and aortic stenosis. The 
EuroSCORE considers 17 parameters grouped into three areas: patient related risk 
factors (e.g., age, history of cardiac surgery), cardiac factors (e.g., reduced left 
ventricular ejection fraction [LVEF], recent myocardial infarction), and operation related 
factors (e.g., emergency operation, other than isolated coronary surgery). The 
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EuroSCORE is also used to predict outcomes of patients undergoing cardiac surgery 
(Nashef et al., 1999). VARC-2 noted limitations in the predictive ability of STS scores in 
high-risk patients with valve disease, however.  
In the most recent review of TAVR research literature, Tang and colleagues 
(2013) also recommended developing better risk scoring and frailty assessment to 
determine especially high-risk patients. Patient selection criteria continue to be clarified 
and physical frailty, malnutrition, chronic kidney disease, history of lung, liver, and 
kidney malignancy, and neurological disorders (e.g., dementia, stroke) were highlighted 
for continued examination to help determine outcomes and the likelihood of patient 
return to a semi-independent daily living status.  
Tang et al. (2013) and VARC-2 recommended a “heart-team” patient-centered 
approach to design an individualized optimal management strategy for TAVR 
candidates (Kappetein et al., 2012).  VARC-2 recommended a “dynamic” team including 
interventional cardiologists, cardiovascular surgeons, imaging specialists, 
anesthesiologists, geriatricians, and neurologists. A main goal of this team is to evaluate 
patient risk-benefit ratio to identify “treatment responders vs. non-responders” 
(Kappetein et al., 2012, p. 1441). Evaluation criteria to make this evaluation includes 
risk of irreversible morbidity, mortality, and expected improvement in QOL.  
Of note, Vahanian et al. (2008), VARC-1, VARC-2 and Tang et al. (2013) did not 
discuss assessment of mental health for either evaluating outcomes or predicting 
patient benefit, nor was the inclusion of a mental health provider mentioned as a 
member of a heart-team. In the years since Vahanian et al. made their 
recommendations, TAVR procedures have increased 50 fold and have been conducted 
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in over 40 countries (Tang et al., 2013). The use and adherence to the 
recommendations by Vahanian et al., VARC-1, VARC-2, or Tang et al. nationally is 
unknown and the inclusion of psychological factors in research has been extremely 
limited. 
Biopsychosocial Model and TAVR 
The biopsychosocial model emphasizes the way in which psychological and 
social processes interact with biological processes as a way to more completely 
understand illness (Engel, 1977). In this model, an illness may have initial medical 
causation, the symptoms and trajectory of which may be exacerbated by social factors 
(e.g., family conflict, loneliness) and/or by psychological factors (e.g., depression, 
anxiety). Medical illness may also have psychological or social precipitants, as when 
anxiety triggers physiological responses (e.g., cortisol release) that suppress the 
immune system, leading to contracting medical disease that would have otherwise been 
defeated by natural antibodies. The usefulness of the biopsychosocial model of illness 
in general, and in heart disease in particular, has been supported by an abundance of 
studies since Engel first proposed the model in 1977 (Biderman, Yeheshkel, & Herman, 
2005; Marušič, Gudjonsson, Eysenck, & Starc, 1999).   
The TAVR procedure attempts to return patients to a relatively normal 
functioning but does not always succeed. The physical reasons for poor outcomes have 
received much attention but it is also possible that poor outcomes may have a 
psychological component. For example, in some cases, people with heart disease who 
inordinately experience negative emotions and social inhibition may fare worse 
(Pedersen & Denollet, 2006). In other cases, recovery may be hindered by a patient’s 
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psychological state such as clinical depression or anxiety (Foxwell, Morley, & Frizelle, 
2013). Even as patient outcomes may be impacted by psychological factors, it is has 
also been shown that psychological factors can have a role in predicting patient 
outcome. For example, depression has been found to predict adherence in weight loss 
programs with more severely depressed individuals having a greater likelihood of either 
dropping out or maintaining static weight (Somerset, Graham, & Markwell, 2011). A 
meta-anaylsis by Rugulies (2002) found that depression predicted the development of 
coronary heart disease (CHD) among those who were initially healthy. A better 
understanding of biopsychosocial factors will better inform prospective patients and 
health providers of the pros and cons of TAVR. Psychological predictors, if found, may 
inform patients to consider psychological intervention that may result in improved 
physical gains. Improvements in outcomes provided by psychosocial care will not only 
provide better patient satisfaction and health, but will also reduce medical costs through 
increased patient engagement in relationships and life activities that help to strengthen 
both body and mind. 
The following is a chronological review of select QOL research related to TAVR. 
Brief descriptions of the measures used are included within this review, with more 
complete descriptions and psychometric data provided at Appendix B.  
Psychosocial and QOL Data for TAVR Patients 
In the first study examining QOL in TAVR patients, Ussia et al. (2009) 
administered the Short Form-12 Health Survey (SF-12) to consecutive patients (N = 30) 
at both pre-op and at 5 months post-op. The SF-12 is a twelve-question survey that 
measures functional health and well-being from the patient’s perspective (Ware et al., 
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1996). The average age of the sample was 81.7 years, 43% male, 93% were NYHA 
Class II or III, and they had markedly worse QOL at pre-op as measured by the SF-12 
than an age-matched general population. Post-op results demonstrated a significant 
improvement in the mean physical component score (28.5 vs. 41.3, p < 0.001) and 
mental component score (37.8 vs. 48.3, p < 0.001). There was also marked 
improvement in physical functioning, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional and mental health scores. In addition, there was 
significant improvement in NYHA class (2.7+0.6 vs. 1.8+0.5, p < 0.001). None of these 
patients reported worse QOL after the TAVR procedure.  
In the first of only two randomized studies examining QOL in TAVR patients, 
Reynolds et al. (2011) compared two groups of patients (N = 358) who either underwent 
TAVR or standard therapy. The TAVR group scored significantly higher on QOL than 
the standard therapy group at all time points after baseline with mean between-group 
differences ranging from 13 to 26 points (p < 0.001) as assessed with the KCCQ. The 
TAVR group also scored significantly higher on the physical and mental health scores of 
the SF-12 at each time point (5.7 and 6.4 points, respectively; p < 0.001). The gains 
experienced by TAVR patients compared to standard therapy demonstrate significant 
patient benefit to QOL. In addition, within-group differences in the TAVR group were 
significant on both measures at each time point (see Table 2). This magnitude of 
difference can also be considered clinically significant. 
In a second randomized study, Reynolds et al. (2012) evaluated QOL at multiple 
time points in two groups of high-risk patients (N = 628) with severe aortic stenosis who 
underwent either TAVR or SAVR. Within-group differences for the group randomized to 
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transfemoral TAVR (n = 230) are displayed at Table 2 and show significant 
improvement on all measures. Participants randomized to transapical TAVR 
demonstrated many of the same benefits as the transfemoral TAVR group although 
generally to less degree. Baseline characteristics of both groups were similar and while 
the researchers suggested several possible reasons for the differences, they admitted 
that an explanation for the differences was unclear. They found that patients who 
underwent transfemoral TAVR demonstrated substantially more health benefits at one 
month post-op than those who underwent SAVR as measured by the KCCQ (difference, 
9.9 points; 95% CI: 4.9 to 14.9; p < 0.001), SF-12 (difference on PCS, 2.0 points; 95% 
CI: 0.1 to 3.9; p = 0.04; MCS, 5.4 points; 95% CI: 3.1 to 7.7; p < 0.001), and Euroqol-5D 
(EQ-5D) (difference, 0.06 points; 95% CI: 0.02 to 0.01; p = 0.008). The EQ-5D is a 
preference/utility-based measure that describes five dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression (Herdman et al., 2011). There 
were no significant differences between TAVR or SAVR groups on either the KCCQ, 
SF-12, or EQ-5D at 6 or 12 months. These results suggest there are likely immediate 
QOL benefits from the less-invasive procedure but once physical recovery is complete, 
TAVR and SAVR patients seem to share equivalent QOL benefits over time.  
Fairbairn and colleagues (2012) assessed the benefits of TAVR and also 
examined predictors of outcomes at multiple time points. The SF-12 and EQ-5D was 
administered to TAVR patients (N = 102) at pre-op and three subsequent times post-op, 
to evaluate the benefits to health related QOL and to find predictors of patient benefit. 
Results from the SF-12 demonstrated significant patient improvement at six months on 
the PCS (29.5 vs. 38.3, p < .001) but not on MCS (45.4 vs. 47.4, p = 0.71). The 
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researchers also calculated disease burden from participant responses to the SF-12 by 
using the Short Form-6D (SF-6D) to measure quality-adjusted life years (QALYs) 
(Phillips, 2009). QALYs are established by considering the quality and quantity of life 
gained by medical interventions, as well as the financial cost of the intervention. EQ-5D, 
VAS and SF-6D scores all significantly improved (54 vs. 65, p < 0.001; 51.1 vs. 68.2, p 
= 0.008; 0.60 vs. 0.69, p = 0.001, respectively). The results from the SF-12 indicated 
that the benefits of TAVR were experienced in the physical realm more than the mental 
realm in this sample.  
Fairbairn et al. (2012) also assessed predictors of change using a general linear 
model. Male sex, patients younger than 80, and patients operated on by a more 
experienced surgeon had significantly greater improvement than the other groups, while 
patients with higher baseline NYHA functional class reported less improvement. The 
largest improvements in QOL happened at the 30-day post-op measures compared to 
subsequent time points. Baseline assessment found that these TAVR patients had 
worse scores on all of their measures compared with age-matched, general U.S. 
population norms. At the 6-month assessment, however, the results of the TAVR group 
were better than the same aged US norms on the EQ-5D, VAS, and the physical 
component score of the SF-12, with similar scores on the SF-6D and the mental 
component score of the SF-12. 
Krane et al. (2012) reported on TAVR patients (N = 106) who completed the SF-
36 at baseline, 3 months post-op, and one year post-op. At three months, the physical 
component scores improved from 31.8 to 37.8 (p < .001), while mental component 
scores remained approximately the same (48.6 vs. 47.9, p = 0.67). At one year, there 
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were similar results on the physical component scores  (31.8 vs. 36.9, p < 0.001) and 
mental component scores (48.6 vs. 49.6, p = 0.18). Of note, their overall SF-36 scores 
were similar to age-matched norms for the standard population at both three months 
and one year. The NYHA class improved significantly at both three month and 12-month 
follow-up as well (3.1 vs. 1.9/2.0, p < 0.001). Krane et al. also assessed patient-related 
and non-patient, procedure-related factors predictive of improvement. More severe STS 
risk score was associated with lower QOL benefits at three months, but there were no 
associations with QOL found for a host of other examined factors including height, 
weight, EF, comorbidities, and COPD. The majority of patients reaffirmed their decision 
to undergo TAVR at both 3 months and 12 months (86.2% and 88.6% respectively). 
Only one study to date has examined anxiety or depression in TAVR patients 
with a measure specifically designed for that purpose. Amonn et al. (2013) assessed 
QOL and psychosocial well-being in high-risk valve patients (N = 144) using the SF-36 
and Hospital Anxiety and Depression Scale (HADS) at 15 ± 10 months post-op. The 
HADS is a 14-item measure that assesses depression and anxiety in hospital settings 
(Zigmond & Snaith, 1983). No baseline assessment was done with these measures. 
Fifty-one patients underwent transapical TAVR and 93 underwent SAVR. Notably, the 
TAVR group had a much higher logistic mean EuroSCORE (26.5 vs. 12.1), higher 
NYHA class (67% vs. 47% were in NYHA Class III or IV) and lower LVEF (mean of 49.6 
vs. 58.1) at baseline suggesting worse disease severity. The rate of mortality was 
similar 30 days post-op but was lower for the SAVR group at final follow-up.  
Scores were not significantly different between groups on the HADS with mean 
scores on the anxiety subscale of 4 for each group, and 4 and 5 for depression in the 
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TAVR and SAVR groups respectively. The only score that was significantly different on 
the SF-36 was that of the general health subscale (52.4 vs. 64.1, p < .005), on which 
the TAVR patients had much lower scores. The only statistically significant predictor 
was that higher STS scores predicted lower post-operative SF-36 scores (p < 0.007). 
Over 80% of both groups reported substantial improvement in general health as a result 
of their procedure and 87.1% of TAVR patients and 94.3% of SAVR patients reaffirmed 
their decision for surgery at post-op assessment. While important, this study is unable to 
draw conclusions about the effects of TAVR on symptoms of anxiety or depression 
because the researchers did not administer the HADS pre-operatively and thus cannot 
compare baseline scores to post-op scores to assess change. Moreover, while the 
absolute percentages of post-operative distress are generally consistent with other 
areas of cardiac psychology, the conclusions that can be drawn based on this single 
study are limited. 
Summary of Previous TAVR Psychosocial and QOL Research  
Table 2 
Summary of studies assessing QOL in TAVR patients  
Author N Lost to   
mortality 















(# of sites) 
Ussia et al. 
(2009) 
30 8 (27) 81.7 
± 4.7 
17 (57) 5 SF-12v2 PCS: 28.5 to 41.3 (p < .001) 
MCS: 37.8 to 48.3 (p < .001) 
2.7 vs. 1.8 




et al. (2010) 
54 6 (11) 79.1 
± 7 
22 (50) 1 MLHFQ 44 vs. 28 (p < .001) 3.0 vs.1.9 
(p < .001) 
*** Germany 
(1) 
Krane et al. 
(2010) 




3 SF-36 PSS: 31.2 to 38.6 (p < .001) 
MSS: 48.5 to 47.3 (p = .5) 
3.1 vs. 1.9 




et al. (2010) 
87 7 (8) 86 ± 
2.9 
47 (59) 6 SF-36 PSS: 28.4 to 46.8 (p < .001) 
MSS: 37.3 vs. 50.6 (p < .001) 
3.1 vs. 1.4 




et al. (2011) 
36 6 (17) 80.5 
± 5.9 




PSS: 21.6 vs. 46.7 (p < .001) 
MSS: 42.9 vs. 55.2 (p < .001) 
MCS: 22 vs. 48.9 (p < .001) 
PCS: 43.3 vs. 52.2 (p < .001) 
3.0 to 1.2 




et al. (2011) 
70  14 (20) 78 ± 
6.6 
26 (51) 12 ± 1 MLHFQ 39.6 vs. 26.1 (p < .001) *** *** Germany 
(1) 
Ussia 
et al. (2011) 
143  *** 81 ± 
4.6 
85 (59) 5 
12 
SF-12v2 PCS: 28.3 vs. 44.0 (p < .001) 
MCS 38.0 vs. 47.3 (p < .001) 
PCS: 28.3 vs. 42.4 (p < .001) 
MCS 38.0 vs. 48.2 (p < .001) 





179 55 (31) 83 ± 
9 

















36.2 vs. 61.6 
PCS: 28.2 vs. 34.6 (p < .001)   
MCS: 44.5 vs. 47.9 (p < .03)  
36.2 vs. 70.7 
PCS: 28.2 vs. 36.0 (p < .001)  
MCS: 44.5 vs. 51.0 (p < .001) 
36.2 vs. 69.4 
PCS: 28.2 vs. 34.9 (p < .001)     
MCS: 44.5 vs. 53.3 (p < .001)  
*** *** USA (21) 
Fairbairn et 
al. (2012) 
99 20 (20) 80 ± 
6 


















PCS: 29.5 vs. 36.3 (p < .001) 
MCS: 45.4 vs. 46.4 (p = .47) 
54 vs. 65 (p < .001) 
PCS: 29.5 vs. 38.3 (p < .001) 
MCS:45.4 vs. 47.4 (p = .71) 
54 vs. 68 (p = .006) 
PCS: 29.5 vs. 34.4 (p < .02) 
MCS: 45.4 vs. 46.9 (p = .58) 
54 vs. 65 (p = .001)  
*** *** UK (1) 
Krane et al. 
(2012) 







SF-36 PSS: 31.8 vs. 37.8 (p < .001) 
MSS: 48.6 vs. 47.9 (p = .67) 
PSS: 31.8 vs. 36.9 (p < .001) 
MSS: 48.6 vs. 49.6 (p = .18) 
3.1 vs. 1.9  
(p < .001) 
3.1 vs. 2.0 







et al. (2012)  
100 *** 79.7 
±  
6.1 
46 (46) 24 SF-36v2  
 
MLHFQ 
PSS: 31.9 vs. 51.5 (p < .0001) 
MSS: 44.7 vs. 49.5 (p = .0002) 
41.5 vs. 15.9 (p < .0001) 
*** *** Italy (1) 
Reynolds et 
al. (2012)**  




























39.3 vs. 63.0 (p < .001) 
PSS: 29.7 vs. 34.7 (p < .001) 
MSS: 47.0 vs. 51.3 (p < .001) 
.66 vs. .74 (p < .001) 
39.3 vs. 69.1 (p < .001) 
PSS: 29.7 vs. 36.4 (p < .001) 
MSS: 47.0 vs. 52.1 (p < .001) 
.66 vs. .76 (p < .001) 
39.7 vs.68.4 (p < .001) 
PSS: 29.7 vs. 36.0 (p < .001) 
MSS: 47.0 vs. 52.0 (p < .001) 
.66 vs. .75 (p < .001) 





Kala et al. 
(2013)  
30 *** *** *** 1, 3, 12 EQ-5D 50 vs. 67 (p < .001) **** 
 
*** *** Czech. (1) 
Goncalves 
et al. (2013)  




6.5 MLHFQ PD: 23.2 vs. 8.6 (p < .001)  
ED: 5.4 vs. 2.6 (p < .0001) 
2.9 vs. 1.4 
(p < .001) 
94.3 Spain (1) 
Amonn et 
al. (2013)  
51 16 (31) 79.7 
± 9.2 
25 (49) 15 ± 10 SF-36 
HADS 















.66 vs. .73 (p < .001) 
 
.66 vs. .73 (p < .0001) 
3.2 vs. 2.0 
p < .001 
3.2 vs. 1.9 
p < .001 
*** France (1) 
* 43 refused follow-up assessment 
** Data for transfemoral TAVR group only 
*** Insufficient data 
**** 12 month data only 
***** Measures only assessed at follow-up 
 
PCS: physical component score 
MCS: mental component score 
PSS: physical summary score 
MSS: mental summary score 
PD: physical dimension 
ED: emotional dimension 
 
A summary of the results from all TAVR studies that have examined QOL is 
provided in Table 2. These studies have consistently and uniformly shown that TAVR 
patients report improved QOL concerning physical health post operatively as measured 
by the SF-36 family of assessments (Amonn et al., 2013; Bekeredjian et al., 2010; 
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Fairbairn et al., 2012; Georgiadou et al., 2011; Krane et al., 2010; Krane et al., 2012; 
Ussia et al., 2009; Ussia et al., 2011; Reynolds et al., 2011; Reynolds et al., 2012; 
Tarmasso et al., 2012). All but three studies (Fairbairn et al., 2012; Krane et al., 2010; 
Krane et al., 2012) have also shown significant improvement in mental QOL. Studies 
have also uniformly demonstrated improved QOL as measured by disease specific 
measures of QOL including the MLHFQ (Goncalves et al., 2013; Gotzmann et al., 2009; 
Gotzmann, 2011; Tarmasso et al., 2012), and the KCCQ (Reynolds et al., 2011; 
Reynolds et al., 2012), as well as a general measure of QOL, the EQ-5D (Elmalem et 
al., 2014; Fairbairn et al., 2012; Kala et al., 2013; Reynolds et al., 2012). In at least two 
studies, these gains were so substantial that TAVR patients reported QOL as good or 
better than norms for their age (Fairbairn et al., 2012; Krane et al., 2012). They also 
provide evidence that many patients experience improvements in QOL within the first 
month after TAVR (Fairbairn et al., 2012; Gotzmann et al., 2009; Reynolds et al., 2011; 
Reynolds et al., 2012). Several studies showed reported reduction in NYHA class 
(Bekeredjian et al., 2010; Georgiadou et al., 2011; Goncalves et al., 2013; Gotzmann et 
al., 2009; Krane et al., 2010; Krane et al., 2012; Ussia et al., 2009). Several studies also 
found that a very large percentage (85 – 94%) of TAVR patients were satisfied with their 
decision to undergo TAVR (Amonn et al., 2013; Goncalves et al., 2013; Krane et al., 
2010; Krane et al., 2012). These findings begin to establish a trend that TAVR patients 
are experiencing QOL benefits in more than one domain.  However, the exact nature of 
those benefits is less clear. Many are physical and/or mental in nature, but it is also 
likely that some are psychological. While one study used a measure that specifically 
measured emotional health (Amonn et al., 2013),  the measure was not administered at 
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baseline and was used primarily to compare differences between SAVR and TAVR 
groups post-operatively with no differences found.  
While this body of literature is significant, as with any study, there are limitations 
in the findings and conclusions that can be drawn. First, all but the two studies by 
Reynolds are single-center studies done in European countries with relatively small 
sample sizes.  Second, the ability to generalize results to US and other populations may 
be limited. Third, in all of these studies for which there is mortality data, a substantial 
number of patients died before completion of follow-up creating the potential of selection 
bias.  Fourth, time of follow-up was limited to one year in all but one study (Amonn et al. 
2013) and that study was cross-sectional with a wide variability in time of assessment 
since surgery. Extended time points would be more meaningful in ascertaining the long 
term effects of TAVR on QOL. Fifth, only four studies had comparison groups (Amonn 
et al., 2013; Kala et al., 2013; Reynolds et al., 2011; Reynolds et al., 2012). No studies 
had control or placebo groups for understandable reasons. While that would have 
provided the strongest test of the specific effects of TAVR, because of the disease state 
of these patients it would be unethical to conduct such studies. Only two of the four 
studies with comparison groups were randomized (Reynolds et al., 2011; Reynolds et 
al., 2012) so differences in between-group results in Kala et al. and Amonn et al. and 
within-group differences in the other studies may be influenced by differences in 
baseline characteristics of the study population. Lastly, while predictors of outcomes 
were examined by a few of these studies (Amonn et al., 2013; Bekeredjian et al., 2010; 
Fairbairn et al., 2012; Krane et al., 2012), the factors that were considered varied and, 
therefore, there is no consensus on what predicts positive or negative health outcomes.  
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Patient Characteristics for Future Research 
While several studies have examined QOL in TAVR research, many other 
important patient characteristics have received little attention. The following is a brief 
summation of information concerning important patient characteristics that merit 
investigation in this patient population.  
 Psychological distress. Psychological distress is a general term that can be 
used to describe the unpleasant symptoms of the two most common psychological 
disorders, anxiety and depression (Poole et al., 2015). 
 Anxiety. Anxiety disorders are the most common psychological disorders, 
affecting 30% of the general population (Kessler, Chiu, Demler, & Walters, 2005). The 
presence of an anxiety disorder has been associated with increased prevalence of a 
variety of physical ailments including hypertension (Johannessen, Strudsholm, 
Foldager, & Munk-Jørgensen, 2006), diabetes (Atlantis, Vogelzangs, Cashman, & 
Penninx, 2012), and peptic ulcer disease (Goodwin & Stein, 2002). Elevated levels of 
anxiety in cardiac patients have been found in numerous studies (Fan, Strine, Jiles, & 
Mokdad, 2008; Kawachi et al., 1994; Kubzansky, Cole, Kawachi, Vokonas, & Sparrow, 
2006; Rozanski, Blumenthal, Davidson, Saab, & Kubzansky , 2005). Anxiety is believed 
to affect the function of the heart by exacerbating electrical instability (Rozanski, 
Blumenthal, & Kaplan, 1999) and contributing to atherogenesis (Kubzansky & Kawachi, 
2000; Manuck and Krantz, 1986). Shen et al. (2008) used four scales of the MMPI to 
assess anxiety in men (N = 635) over an average of 12.4 years. They created an overall 
index scale of anxiety using factor analysis and found that anxiety-prone dispositions 
were a strong risk factor for MI. Fan et al. (2008) examined measures of anxiety, 
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depression, and other behavioral risk factors on a large national sample (N = 129,499) 
of people over the age of 44 and found that participants who had a lifetime history of 
anxiety disorders were more likely than others to have either angina, coronary heart 
disease, MI, or stroke (16.6% vs. 10%). Existing research implicates anxiety as playing 
a potentially significant role in cardiac disease and the possibility that anxiety level may 
be a predictor of health outcome in TAVR patients warrants investigation.  
Depression. There is broad evidence that depression is associated with 
increased risk of adverse cardiovascular events and mortality (Barth, Schumacher, & 
Hermann-Lingen, 2004; Blumenthal et al., 2003; Carney, Freedland & Shepps, 2004; 
Frasure-Smith, Lesperance, & Talajic, 1995). Major depressive disorder is also 
prevalent in patients with CVD with estimates ranging from 15-40% (Office of Disease 
Prevention and Health Promotion, 1998). Depression is also associated with health 
behaviors that increase the risk of CVD including smoking, poor dietary habits, non-
adherence to medication regimen, and sedentary lifestyle (Kop & Plumhoff, 2012). 
Depression has been found to be a significant predictor of morbidity, mortality, and low 
QOL in patients with severe heart disease (Mallik et al., 2005). Mallik et al. assessed 
patients who underwent CABG (N = 963) using the Geriatric Depression Scale (GDS) 
and the physical component scale of the SF-36. Patients with a GDS score of < 5 
experienced a mean improvement of 60.1% on physical function, patients with a score 
between 5 and 9 experienced an improvement of 49.8%, while patients with a GDS 
score of > 9 experienced an improvement of 39.7% (p = 0.002).  The authors found that 
an elevated score on the GDS (> 9) was a stronger predictor of poor physical well-being 
than other measures of disease severity such as previous MI, heart failure on 
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admission, history of diabetes, and LVEF. In a recent meta-analysis, Lueng et al. (2012) 
reported that both pre-morbid and post-morbid depression was associated with worse 
outcomes in patients with coronary heart disease. Based on studies such as these, 
depression appears to be associated with worse outcomes in patients with heart 
disease. Therefore, examining the effects of depression in TAVR patients is particularly 
warranted.  
Positive Psychology/Resilience Factors. Patient factors that fall within the 
realm of both positive psychology and resilience have been found to be associated with 
health outcomes. These factors include such components as satisfaction with life, will to 
live, and positive health expectations. 
Satisfaction with life. Satisfaction with life as a whole is considered an 
important component of subjective well-being (Pavot & Diener, 1993; Lyubomirsky, 
King, & Diener, 2005) and has been found to be associated with improved physical 
health outcomes such as reduced risk of aortic calcification (Matthews, Owens, 
Edmundowicz, Lee, & Kuller, 2006), fewer emergency room and hospital visits (Gil et 
al., 2004), fewer illnesses (Goldman, Kraemer, & Salovey, 1996), and longevity (Levy, 
Slade, Kunkel, & Kasl, 2002). Life satisfaction has also been found to be associated 
with improved outcomes such as academic success (Borello, 2005) reduced suicide risk 
(Koivumaa- Honkanen, et al. 2001), and expectation for success (Wright & Mischel, 
1982). While this construct has yet to be included in any previous investigations of 
TAVR, given the rising importance and role that both positive and negative affect can 
play, assessment of this construct was included in the current study to determine if it 
was associated with post-op quality of life gains .  
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 Will to live. Clinical lore among surgeons has long speculated about the role will 
to live may play in patient outcomes and, in fact, research suggests that patient will to 
live may play a crucial role in mortality (Levy, Slade, Kunkel, & Kasl, 2002; Phillips & 
Feldman, 1973; Ray, 2004; Shimizu & Pelham, 2008). Shimizu and Pelham (2008) 
replicated previous studies that had suggested that people were able to defer death 
until after meaningful events (e.g., holidays, birthdays) by analyzing a database of over 
30 million decedents and found that people were more likely to die on days following an 
event like Christmas, than on the days preceding. Levy et al. (2002) analyzed a 
database of 660 individuals aged 50 and older and found that those with positive self-
perceptions of aging lived 7.5 years longer than those with less positive self-perceptions 
(p < 0.001). They assessed will to live with three items asking patients to rate the 
degree to which their life was empty-full, hopeless-hopeful, and worthless-worthy with 
one item of each pair on the opposite ends of a seven point scale. They found that a 
patient’s will to live partially mediated the relationship between positive self-perceptions 
of aging and longer life. Further, Martickainen & Valkonenen (1996) studied married 
couples ages 35 to 84 (N = 1.5 million) and found they were more likely than normal to 
die within the six months after their spouse had died, suggesting an increased 
vulnerability to disease. Reasons for this vary but one hypothesis is that having a 
spouse may help keep people engaged in healthy behaviors and thus, the loss of one’s 
spouse decreases such behaviors, hastening mortality. Alternatively, the loss of a 
spouse may result in weakening the survivor’s will to live as part of the grieving process. 
Further, since almost all TAVR patients are quite elderly and face multiple health issues, 
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it may be that a patient’s will to live may waver in light of heightened perceptions of the 
inevitability of death.  
Positive health expectations. Positive expectations about the future have been 
found to be associated with better mental and physical health by a number of studies 
(Peterson & Bossio, 2001; Scheier et al., 1989; Taylor & Brown, 1988). Optimistic 
outlook may increase the likelihood one will adopt adaptive coping strategies like 
problem-solving rather than avoidance (Nes & Segerstrom, 2006) and may also result in 
better response to stressors (Aspinwall & Taylor, 1997). Leedham, 
Meyerowitz,Muirhead & Frist (1995) examined the relationship between positive 
expectations and health in heart transplant patients and found they were associated 
with patient adjustment and QOL. Sears et al. (2004) found that cardiac patients with 
high health expectations reported better general health at follow-up after controlling for 
important baseline cardiac health factors. Therefore, results from studies examining the 
effects of health expectations in a group of elderly, frail TAVR patients may provide 
evidence for the need to develop interventions to improve QOL in this population. 
Behavioral factors. Important behavioral factors that merit investigation in TAVR 
patients include physical activity, shortness of breath, and medication adherence. The 
relevance of these factors concerning this patient population is described in detail 
below. 
Physical activity. The benefits of physical activity and the consequences of the 
lack of physical activity have been documented in an abundance of literature (Physical 
Activity Guidelines Advisory Committee, 2008). While the elderly are one of the least 
active population groups, there are a variety of benefits they may gain from improved 
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physical activity including less depression, improved independence, better cognitive 
functioning, and better overall QOL (Nelson et al., 2007). However, to date we have no 
understanding about the activity patterns of TAVR patients and how they may play a 
role in treatment outcomes. Therefore, obtaining information about self-reported 
physical activity levels at baseline and post-TAVR may help increase understanding of 
the physical benefits of TAVR and whether pre-TAVR physical activity levels may be a 
predictor of other health outcomes.  
 Shortness of breath. Shortness of breath, also known as dyspnea, is one of the 
most prominent symptoms of aortic valve disease (Carabello, 2013).  Worsening 
dyspnea often means a worsening prognosis in valve disease. Dyspnea is one of 
several symptoms, that when occurring alone in the presence of severe aortic stenosis, 
may result in recommendation for valve replacement (Shah, 2012). Dyspnea is one 
factor that inhibits people with valve disease from living a full and active life and 
improvement in dyspnea may be expected after TAVR. As such, patient self-report of 
symptoms of dyspnea provides one measure of improvement post-TAVR and may also 
be found to be a predictor of QOL as well. 
 Medication adherence. Non-adherence to medication protocol has been defined 
as taking medications as prescribed only 75% of the time or less (Gehi, Ali, Na & 
Whooley, 2007). The estimated average adherence rates to medication instructions in 
cardiac patients has been found to be between 51% to 79%, depending on the number 
of daily doses (Horwitz et al., 1990). Therefore, better understanding the extent to which 
patients adhere to their medication regimen would certainly impact the benefits they 
could gain from TAVR. 
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Summary 
TAVR has been found to be an extremely beneficial surgical procedure for 
treating patients contraindicated for SAVR. The effects of TAVR in improving QOL have 
consistently been demonstrated in the past 12 years. TAVR is a relatively new medical 
procedure and research to date has provided a starting point for gaining an 
understanding of the outcomes of TAVR and for examining possible predictors of 
outcomes. However, several important factors have not been examined to date that 
could play a significant role in treatment outcome and have significant implications for 
patient care. As emphasized in this literature review, almost all patient characteristics 
that are psychological in nature have been neglected in TAVR research. In addition, 
important physiological characteristics and health behaviors in patients with valve 
disease have been unaddressed. The overarching aim of this proposed research is to 
provide a better understanding of the psychological and physiological benefits of TAVR 
and to gain a better understanding of patient characteristics associated with desirable 
health outcomes.  
Study Aims  
Aim 1. The first aim of this study was to describe the characteristics of a 
population of TAVR patients (who were contraindicated for SAVR) on the demographic 
data and measures described above. Baseline data on physical activity, anxiety, 
depression, life satisfaction, positive health expectations, dyspnea, and will-to-live have 
not previously been gathered on TAVR patients. This data provides information to future 
TAVR patients and health care providers on the preoperational biopsychosocial 
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condition of valve patients. The first aim was accomplished by gathering baseline 
characteristics by counts, percentages, and mean ± SD where appropriate.  
Aim 2. The second aim of this study was to describe changes in TAVR patients 
on physical activity, generic and disease-specific, anxiety, depression, dyspnea, and 
will-to-live between baseline and 3-months post-op. The advantage of testing each 
patient against his or her baseline value is that it corrects for any potential survivor bias 
due to participant mortality. Based on the non-normal distribution of scores, the second 
aim was accomplished by determining differences in the results of each measure from 
baseline to 3-months by using the Wilcoxon Signed Rank Test.  
Based on previously described research, it was expected that physical activity, 
QOL, and dyspnea would demonstrate significant improvement as a result of TAVR. It 
was not expected that anxiety, depression, or will-to-live would change significantly as 
those states are generally a result of many more factors than TAVR would directly 
impact. 
Aim 3. The third aim of this study was to analyze possible predictors of change in 
QOL in TAVR patients as measured by the SF-12v2 and KCCQ at 3-months post-op. 
Predictors that were analyzed independently included baseline measures of QOL, 
anxiety, depression, life satisfaction, positive health expectations, dyspnea, and will-to-
live. The expectation was that participants with lower baseline QOL and higher dyspnea 
would experience greater increases on QOL as a result of TAVR alleviating problematic 
cardiac symptoms that were negatively impacting QOL. The hypothesis was that higher 
scores on anxiety and depression would be associated with decreased change in QOL. 
Higher scores on positive health expectations, life satisfaction, and will-to-live were 
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expected to be associated with increased improvement in QOL because higher scores 
are associated with greater propensity for positive experiences. Due to the non-normal 
distribution of scores, a regression analysis was conducted to determine the relationship 
between each predictor and change in QOL post-TAVR using Spearman’s Rho.  
The information gathered from this aim may help health care providers better 
identify patients who may and may not benefit from TAVR. In some cases, early 
identification may allow for treatment (e.g., pharmacologic or psychological therapy in 
the case of depression) that may increase the likelihood of positive outcomes of 
surgery. These psychosocial and physiological predictors have not yet been assessed 
in TAVR research.  
	  Chapter III: Method 
Participants 
This study was conducted with patients who had been indicated for TAVR and 
contraindicated for SAVR, after receiving care at the East Carolina Heart Institute 
Outpatient Clinic in Greenville, NC or the St. Thomas Research Institute, Nashville, TN. 
Patients were required to speak and read English, be 18 or older, and be able to 
cognitively complete questionnaires with assistance from research assistants. The initial 
expectation was that recruiting 30 patients for the study by May 2014 would be possible 
based on past history of the number of TAVR procedures performed at this site. That 
did not prove possible and only 15 were recruited with one of those dying within one 
week of recruitment and another declining in mental capacity to the point where her 
ability to complete the questionnaire with meaningful data was compromised. Therefore, 
the study opened another site in Nashville, TN and from that site 21 participants were 
successfully recruited for a total of 34 participants.  
This study received IRB approvals for East Carolina University (ECU) (Appendix 
A) and the IRB board at ECU also provided oversight for the St. Thomas site. No
subjects were compensated financially or otherwise for participation in this study. 
Measures 
Participants completed a short questionnaire consisting of questions about 
demographics, generic QOL, disease-specific QOL, psychological distress, and positive 
psychology/resilience factors. A description of each section of the survey is provided 
below.  
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Demographics.  Demographic questions include one question each about 
marital status, education, employment status, race/ethnicity, and living situation. 
Generic QOL. The SF-12v2 is a 12-item revision of the SF-36 (Ware et al., 
1996)  and provided a general health measure of QOL for this study. The SF-12 
maintains 90% of the variance of the mental and physical health scales of the SF-36, 
although it has less accurate reproduction of the eight scales of the SF-36. 
Administration time is lowered from five minutes for the SF-36 to two minutes for the 
SF-12. The SF-12v2 is an updated version of the SF-12 that adjusted some of the 
response options. A recent review of the SF-12v2 using a large, adult patient population 
(N = 2,410) found that the mental and physical health scales explained over 80% of the 
total variances of the SF-36v2 (Lam, Lam, Fong & Huang, 2013). The SF-12v2 is 
scored by computer and provides a T-score based on a representative US population 
sample. Recently evaluated Cronbach’s alpha on the physical component scale has 
been found to range from 0.81 - 0.90 (M = 0.87) in various population groups (DeSmedt 
et al., 2013). Cronbach’s alpha on the mental component scale ranged from 0.74 – 0.89 
(mean = 0.84). Due to the complexity of the computerized scoring algorthim used to 
calculate both scale scores of the SF-12, a reliability estimate was unable to be 
computed for the current study. However, both baseline and post-op Cronbach alpha 
coefficients were .82 for the measure as a whole. 
Disease-specific QOL. The KCCQ is a 23-item measure commonly used to 
evaluate the health status of heart failure patients (Creber et al., 2012). The five 
domains addressed by the KCCQ are: symptoms, physical limitation, social limitation, 
self-efficacy, and quality of life and yield nine subscale scores with scores from 0 – 100; 
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higher scores are indicative of fewer symptoms and higher QOL (Green et al., 2000). 
The individual scale scores are combined into an overall summary scale. A change in 
score of 5, 10, and 20 points on any subscale or the overall summary score represents 
a small, moderate, and large change respectively (Reynolds et al., 2012). The KCCQ 
overall summary score has been found to correlate with NYHA functional class as 
follows: Class I is roughly equal to KCCQ summary score of 75 to 100; Class II, to a 
score of 60 to 74; Class III, to a score of 45 to 59; and Class IV, to a score of 0 to 44 
(Spertus et al., 2005). Arnold et al. (2013) evaluated the psychometric properties of the 
KCCQ in patients with severe aortic stenosis and found good construct validity when 
comparing each domain of the KCCQ against a reference measure. In an evaluation by 
Creber et al., the Cronbach’s alpha was 0.92 indicating excellent internal consistency. In 
the current study, the baseline Cronbach alpha coefficient was .93 and the post-op 
Cronbach alpha coefficient was .96. 
Psychological distress (HADS). The HADS is a 14-item measure that assesses 
depression and anxiety and is used primarily in hospital settings (Zigmond & Snaith, 
1983). All somatic symptoms related to depression and anxiety are excluded from this 
measure in order to account for the likely experience of such symptoms from known or 
expected physiological problems in this population. Seven items on the scale assess 
depression and the other seven items assess anxiety. Each item is scored from 0-3 for 
a total possible score of 21 on each scale with higher scores representing higher levels 
of anxiety or depression. The established clinical cutoff for each subscale is eight. A 
review by Bjelland, Dahl, Haug, and Neckelmann (2002) identified over 700 studies that 
used the HADS with the majority confirming the two-factor solution in accordance with 
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the subscales of anxiety (HADS Anxiety) and depression (HADS Depression). 
Cronbach's alphas for HADS-A varied from .68 to .93 (M = .83) and for HADS-D from 
.67 to .90 (M = .82). Mean Cronbach’s alpha values indicate good internal consistency 
for both scales. In the current study, the baseline HADS Anxiety Cronbach alpha 
coefficient was .82 and the post-op Cronbach alpha coefficient was .55. Question three 
on the HADS Anxiety scale (“I get a sort of frightened feeling like ‘butterflies’ in the 
stomach.”) had zero variance in the post-op assessment and was removed for the 
reliability analysis. The baseline HADS Depression Cronbach alpha coefficient was .73 
and the post-op Cronbach alpha coefficient was .80. 
Positive psychology/resilience factors. The positive psychology/resilience 
factors considered in this study are satisfaction with life, will to live, and positive health 
expectations. 
Satisfaction with life scale. This five-question scale developed by Pavot and 
Diener (1993) assesses satisfaction with life as a whole. Participants rate their 
satisfaction with different aspects of their life on a 7-point Likert scale. Possible scores 
range from 5-35 with higher scores indicating greater life satisfaction with a score of 20 
representing the neutral point on the scale. Scores between 5 and 9 indicate that the 
respondent is extremely dissatisfied with life, scores between 10 and 14 indicate 
moderately dissatisfied, scores between 15 and 19 indicate slightly dissatisfied, scores 
between 21 and 25 represent slightly satisfied, scores between 26 and 30 indicate 
moderately satisfied, and scores ranging between 31 and 35 indicate that the 
respondent is extremely satisfied with life. Cronbach’s alpha has been shown to range 
from .79 - .89 (Pavot & Diener, 1993; Adler & Fagey, 2005). This measure was only 
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administered at baseline and in the current study the Cronbach alpha coefficient was 
.89. 
 Will-to-live scale. Participants rated their will-to-live on a single-item VAS with 
anchors of “no will to live” and “absolute will to live”. This scale has been used in one 
other study and had a high correlation with depression, anxiety, desire for death, burden 
to others, and hopelessness (Chochinov et al., 2005). However, its psychometric 
properties have not been evaluated. There are no published scales of measures of will 
to live for which psychometric properties have been evaluated. 
 Positive health expectations scale. The PHE assesses patient beliefs about 
the efficacy of their treatment and their future outlook (Leedham et al., 1995). The scale 
was first used with heart transplant patients and demonstrated good convergent validity 
with QOL scores, divergent validity with mood disturbances scores, and predictive 
validity with physical health measures. Sears et al. (2004) used this measure to assess 
PHE in ICD patients and modified it by adding a question assessing motivation for ICD 
implantation. The current study has similarly modified the PHE with a question 
assessing motivation for valve surgery. Respondents rate their health expectations on a 
7-point Likert scale. There are eight questions and possible scores range from 8 to 56 
with higher scores indicating a more positive outlook. Cronbach’s alpha was 0.81 and 
0.88 in the Leedham et al. and Sears et al. studies respectively, indicating good internal 
consistency. This measure was only administered at baseline. In the current study the 
Cronbach alpha coefficient was .82. 
 Behavioral factors. The behavioral factors examined in this study are physical 
activity, shortness of breath, and medication adherence. 
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Physical activity scale. Five standardized questions concerning physical activity 
were used that came from a questionnaire developed for the Heart and Soul Study 
(Whooley et al., 2008), a large study (N = 1,024) of patients with coronary heart disease 
(CHD). The questions for this study queried participants on the amount of exercise they 
have conducted over the previous month, including one question asking patients to rate 
the amount of exercise they get compared to others their age and sex. The range of 
possible scores was 0-17 with higher scores indicating greater physical activity. In the 
current study the baseline Cronbach alpha coefficient was .64 and the post-op 
Cronbach alpha coefficient was .74. 
Shortness of breath scale. The SOBQ is a self-report questionnaire in which 
patients indicate the severity of shortness of breath experienced during 21 activities of 
daily living that vary in rate of exertion (Eakin, Resnikoff, Prewitt, Ries, & Kaplan,1998). 
Ratings for each item are on a 6-point scale (e.g., 0 = Not at all, 4 = Severely, 5 = 
Maximally or unable to do because of breathlessness). An additional three questions 
inquire about limitations due to shortness of breath, fears about overexertion, and fear 
of shortness of breath. The maximum score is 120 and a change of 5 points is 
considered clinically significant (Ries, 2005). Reliability has been found to be superior to 
other measures of dyspnea including the Baseline Dyspnea Index (BDI), American 
Thoracic Society Dyspnea Scale and the Oxygen Cost Diagram (Eakin et al., 1998). 
Validity has been found to be good after examination of variables with which it is 
believed to be related such as exercise tolerance, health-related QOL, lung function, 
and depression. The study by Eaken et al. had a Cronbach’s alpha value of 0.96 
indicating excellent internal consistency. In the current study the baseline Cronbach 
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alpha coefficient was also .96. The post-op Cronbach alpha coefficient could not be 
computed because only one participant completed all questions. 
In this study, many participants chose not to answer several questions that 
inquired about activities that they had either not done in too great a time period or 
currently engaged in too infrequently to feel comfortable assessing (e.g., washing a car, 
mowing a lawn). Therefore, questions that were answered by fewer than 75% of 
participants (questions 14 and 17-21) were removed from consideration in this analysis. 
The highest possible score in this scale, now entitled Geriatric SOBQ, was 90. 
Participants who answered at least 15 of the 18 questions of the Geriatric SOBQ were 
assigned a score computed on a 90 point scale. In the current study the baseline 
Cronbach alpha coefficient of the Geriatric SOBQ was .95 and the post-op Cronbach 
alpha coefficient was .93. 
Medication adherence scale. Five standardized medication adherence 
questions were used that also came from the Heart and Soul study (Gehi et al., 2007). 
The questions for this study queried participants on the degree to which they adhered to 
their medication protocol over the previous month with a possible range of scores from 
0-25 with lower scores indicating greater adherence. In the current study, baseline
Cronbach alpha coefficient was .67. The post-op Cronbach alpha coefficient could not 
be computed because four of the five questions had zero variance. 
Procedure 
Potential participants were identified by their physician upon arrival and check-in 
at their scheduled TAVR review appointment. Patients indicated for and choosing TAVR 
were approached by a research assistant and given a brief description of the study and 
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invited to participate. If they accepted, the informed consent was reviewed and signed. 
The questionnaire was explained and either self-administered or administered with the 
assistance of the research assistant. Patients were contacted for the subsequent 
administration of the measure via phone or mail three months post-TAVR.  
Statistical Analyses 
Statistical analyses were performed with SPSS® 20.0 (SPSS Inc., Chicago, IL). 
In all analyses, p ≤ .05 was considered significant and no adjustments were made for 
multiple comparisons since the evaluated data were not random and due to concern for 
Type II Error in this novel population (Rothman, 1990). Effect sizes of .1, .3, or .5 were 
considered small, medium, or large respectively (Cohen, 1992) and calculated using the 
convention, r = z / square root of N, where, for between groups comparisons, N = total 
number of cases, while for within group comparisons N = total number of cases 
multiplied by the total number of observations (Pallant, 2007). 
Baseline population characteristics on demographic data and the measures 
described previously were calculated by counts, percentages, and mean ± SD where 
appropriate. Between group comparisons of baseline characteristics were conducted 
using Mann Whitney U based on the non-normal distribution of scores. Changes in 
TAVR patients from baseline to 3-months post-op on physical activity, QOL as 
measured by the KCCQ and SF-12v2, anxiety, depression, dyspnea, and will-to-live 
were assessed by using the Wilcoxon Signed Rank Test based on the non-normal 
distribution of scores. Nonparametric tests were conducted using normal 
approximations (Bellara, Julien, & Hanley, 2010). Possible predictors of change in QOL 
in TAVR patients (as measured by the SF-12v2 and KCCQ) were analyzed 
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independently and included baseline measures of QOL, anxiety, depression, life 
satisfaction, positive health expectations, dyspnea, and will-to-live. A regression 
analysis was conducted to determine the relationship between each predictor and 
change in QOL post-TAVR using Spearman’s Rho due to the non-normal distribution of 
scores.  
	  CHAPTER IV: RESULTS 
Demographic Data 
A total of 39 patients were approached to participate in the study and of these, 36 
agreed for a participation rate of 92%. Two patients declined to participate for unknown 
reasons and one patient declined due to concern that completing the survey would 
induce anxiety. Of the 36 patients who agreed to participate, one died prior to returning 
the baseline survey. Another patient who agreed to participate was later deemed 
ineligible due to cognitive concerns raised by a family member who was also a primary 
care provider. Of the 34 patients completing the baseline survey, thirteen were recruited 
from the East Carolina University Heart Institute site and 21 were recruited from the St. 
Thomas Research Institute site in Nashville, Tennessee. Of the 34 participants,18 
completed the post-op survey for a follow-up rate of 53%. Patients ranged in age from 
52 to 95 with a mean age of 79.2. Baseline demographic characteristics of the study 
group are provided at Table 3 and baseline clinical scores are provided at Table 4. 
Table 3 










Black / African American 
Level of education 
Some high school 
High school graduate or equivalent 
Some college or vocational school 
College graduate 


















Social living status 
Live alone 








Baseline Clinical Scores 
Measure M SD n 
KCCQ 
Overall Summary Score 54.2 25.9 33 
Physical Limitation 53.1 29.4 32 
Symptom Stability 43.4 14.2 34 
Symptom Frequency 55.7 27.3 34 
Symptom Burden 54.2 27.9 34 
Total Symptom 54.9 25.2 34 
Self-efficacy 92.3 16.3 34 
Quality of Life 52.4 29.2 34 
Social Limitation 53.5 32.7 32 
Clinical Summary 54.7 25.3 33 
SF-12 
PCS 28.9 8.8 33 
MCS 53.2 10.3 33 
HADS Depression 6.7 3.8 34 
HADS Anxiety 4.8 4.4 33 
Geriatric SOBQ  33.6 21.5 34 
Satisfaction with Life Scale 24.8 9.1 24 
Positive Health Expectations Scale 46.9 7.9 34 
Physical Activity 4.5 3.7 34 
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Medication Adherence 1.0 1.7 34 
Will to Live 9.5 1.8 33 
Comparisons of Baseline Scores 
Because of the small sample size, the sample was collapsed into no more than 
two groups for each demographic characteristic and examined for clinically relevant 
differences for the following measures: all of the KCCQ scales including the overall 
summary score, SF-12 Physical Component Score, SF-12 Mental Component Score, 
HADS Depression, HADS Anxiety, Geriatric SOBQ, SWL Scale, PHE Scale, and 
physical activity. There was insufficient variability on the Will to Live Scale to conduct 
meaningful analyses. Inspection of data found that they were not normally distributed 
and therefore within group baseline characteristics were examined using the Mann-
Whitney U Test. There were significant baseline differences on some measures based 
on sex, marital status, and age. There were no significant baseline differences based on 
social living status or education level, however.   
Comparisons of Baseline Scores in Men and Women 
Results indicated that there was a significant difference in the KCCQ Symptom 
Burden scores of men (Mdn = 62.6, n = 18) and women (Mdn = 50.0, n = 16), U = 85, z 
= -2.07, p = .038, r = .4, with men reporting less difficulty with symptoms. Higher scores 
on this measure indicate less symptom burden. There was a significant difference in the 
SF-12 Mental Component Scale scores of men (Mdn = 58.6, n = 17) and women (Mdn 
= 49.1, n = 16), U = 66, z = -2.52, p = .012, r = .4, with men reporting better mental 
functioning scores. Again, higher scores on this measure indicate better mental quality 
of life. There was also a significant difference in the HADS Anxiety scores of men (Mdn 
= 2.5, n = 18) and women (Mdn = 5.0, n = 15), U = 76, z = -2.17, p = .03, r = .4, with 
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men reporting lower anxiety scores. The KCCQ Total Symptom score of men (Mdn = 
63.5, n = 18) and women (Mdn = 44.8, n = 16), U = 88, z = -1.93, p = .053, r = .3, 
approached statistical significance. Higher scores indicate greater health quality of life 
as measured by a combination of symptom frequency and symptom burden scores. No 
other differences in baseline clinical characteristics for men or women approached 
statistical significance (Table 5). 
Table 5 
Sex Comparisons of Baseline Scores 
Sex 
Measure Men Women 
   M    Mdn   N    M   Mdn    N 
KCCQ 
Overall Summary 57.7 55.5 18 50.1 48.4 15 
Physical Lim 54.6 29.1 18 51.2 46.9 14 
Symptom Stab 41.7 50.0 18 45.3 50.0 16 
Symptom Freq 62.6 59.4 18 47.9 45.8 16 
Symptom Brdn* 64.4 62.6 18 42.7 50.0 16 
Total Symptom 63.5 65.2 18 45.3 44.8 16 
Self-efficacy 91.7 100.0 18 93.0 100.0 16 
Quality of Life 57.7 62.5 18 46.4 41.8 16 
Social Limitation 57.0 50.0 17 49.4 50.0 15 
Clinical Summary 59.0 60.5 18 49.4 44.8 15 
SF-12 
PCS 28.6 31.9 17 29.3 29.2 16 
MCS*  57.8 58.6 17 48.3 49.1 16 
HADS Depression 6.9 6.5 18 6.5 6.5 16 
HADS Anxiety* 3.7 2.5 18 6.0 5.0 15 
Geriatric SOBQ  30.9 24.6 18 36.7 33.9 16 
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SWL 26.9 31.0 13 22.4 25.0 11 
PHE 47.3 51.0 18 46.6 47.5 16 
Physical Activity 5.2 3.5 18 3.8 3.0 16 
Med Adherence 0.7 0.0 18 1.4 0.0 16 
* p < .05.
Comparisons of Baseline Scores by Age Groups 
There were several age differences across the measures. Older patients in this 
sample appeared to fare better in QOL domains. There was a significant difference in 
the KCCQ Symptom Frequency scores of patients 80 or older (Mdn = 66.7, n = 17) and 
patients under the age of 80 (Mdn = 50.0, n = 17), U = 65.5, z = -2.73, p = .006, r = .5). 
Higher scores indicate greater health quality of life when measured by heart-related 
symptom frequency. There was also a significant difference in the SWL scores of  
patients 80 or older (Mdn = 28.7, n = 12), and patients under the age of 80 (Mdn = 21.0, 
n = 12),  U = 37, z = -2.05, p = .04, r = .4) with higher scores indicating higher life 
satisfaction. In addition, there was a significant difference in the physical activity scores 
of patients 80 or older (Mdn = 5.0 , n = 17) and patients under the age of 80 (Mdn = 3.0, 
n = 17), U = 72, z = -2.52 , p = .012  , r = .4) with patients 80 or older reporting greater 
physical activity.  
Table 6 
Age Comparisons of Baseline Scores  
Age 
Measure < 80 80 + 
M Mdn N M Mdn N 
KCCQ 
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Overall Summary  47.9 47.9 16  60.1 58.0 17 
Physical Lim 46.0 44.8 16  60.3 60.4 16 
Symptom Stab 39.7 50.0 17  47.1 50.0 17 
Symptom Freq* 44.3 50.0 17  67.0 66.7 17 
Symptom Brdn 49.0 41.8 17  59.3 50.0 17 
Total Symptom 46.7 41.8 17  63.2 63.6 17 
Self-efficacy 91.2 100.0 17  93.4 100.0 17 
Quality of Life 50.3 41.8 17  54.4 58.3 17 
Social Limitation 44.8 40.7 16  62.1 50.0 16 
Clinical Summary 46.7 42.7 16  62.2 60.5 17 
SF-12        
PCS  26.3 28.4 17  31.7 32.7 16 
MCS**  50.4 53.7 17  56.1 57.8 16 
HADS Depression 7.5 7.0 17  5.9 6.0 17 
HADS Anxiety 5.7 3.5 16  3.9 4.0 17 
Geriatric SOBQ  38.9 33.0 17  28.4 29.3 17 
SWL*  21.0 20.0 12  28.7 31.5 12 
PHE 47.8 50.0 17  46.1 45.0 17 
Physical Activity** 2.9 3.0 17  6.2 5.0 17 
Med Adherence 1.4 0.0 17  0.6 0.0 17 
*p < .01, **p < .05 
 
Comparisons of Baseline Scores by Current Marital Status 
Comparisons between patients who were currently married and patients who 
were either widowed, currently divorced, or never married found that married 
participants reported somewhat less favorable physical health than the other group at 
baseline. There were significant differences in the SF-12 Physical Component Scale 
scores of married patients (Mdn = 23.1, n = 15) and the widowed, currently divorced, or 
never married group (Mdn = 31.7, n = 18), U = 75, z = -2.17, p = .03, r = .4). Higher 
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scores indicate better physical quality of life. While not quite reaching statistical 
significance, there were differences in the Geriatric SOBQ scores of married patients 
(Mdn = 21.2, n = 15) and the widowed, currently divorced, or never married  group (Mdn 
= 14.6, n = 19), U = 87, z = -1.93, p = .54, r = .3). Higher scores indicate greater 
shortness of breath. No other differences in baseline clinical characteristics for current 
marital status approached statistical significance (Table 7). 
Table 7 
Marital Status Comparisons of Baseline Scores  
Marital Status 
Measure Currently Married Other 
   M    Mdn   N    M    Mdn    N 
KCCQ 
Overall Summary 50.8 46.7 14 56.7 51.6 19 
SF-12  
PCS* 24.9 23.1 15 32.3 31.7 18 
MCS 54.8 56.7 15 51.9 54.7 18 
HADS Depression 7.1 7.0 15 6.5 6.0 19 
HADS Anxiety 4.2 4.0 15 5.2 4.0 18 
Geriatric SOBQ**  41.8 39.2 15 27.2 22.2 19 
SWL  22.4 24.0 10 26.6 29.5 14 
PHE 48.5 50.0 15 45.8 44.0 19 
Physical Activity 5.1 3.0 15 4.1 3.0 19 
* p < .05, **p = .054
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Comparisons of Baseline Scores Based on Level of Survey Completion  
 Between-group analyses were conducted to identify possible baseline 
differences between participants who completed the second survey and those who did 
not because only 18 of the 34 participants completed the post-op survey. Analyses were 
completed using the Chi-square test for independence for categorical variables and the 
Mann-Whitney U test for continuous variables. Both groups were similar and there were 
no significant differences on any variables with the exception of study site location. 
While 100% of the ECU participants completed both surveys, only 24% of the St. 
Thomas participants did, a difference that was statistically significant, X 2 (1, n = 34) = 
15.78, p < .001, phi = -.74.  
Comparisons Between Baseline and Post-op Scores 
 Baseline scores on clinical measures were compared with scores obtained at 
approximately three months post-TAVR (M = 109 days, SD = 19.8). Inspection of data 
found that they were not normally distributed and therefore between groups analyses 
were conducted using the Wilcoxon Signed Rank Test.  
Several statistically significant differences were discovered (Table 8).  There was 
a statistically significant increase in health status post-TAVR as measured by all of the 
KCCQ subscales except Symptom Stability and Self-efficacy. For example, the KCCQ 
Overall Summary Score significantly increased, z = -3.36, p = .001, with a large effect 
size (r = .84). The median score of the KCCQ Overall Summary Score increased from 
baseline (Mdn = 49.8) to post-TAVR (Mdn = 85.7).  There was a statistically significant 
increase in physical QOL as measured by the SF-12 from baseline (Mdn = 27.9) to 
post-TAVR (Mdn = 40.3), z = -2.84, p = .004, with a large effect size (r = .69).  There 
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was also a statistically significant decrease in anxiety post-TAVR as measured by the 
HADS, z = -2.47, p = .014, with a large effect size (r = .58). The median score of the 
HADS Anxiety Score decreased from baseline (Mdn = 4.0) to post-TAVR (Mdn = 1.5). 
Finally, there was a statistically significant decrease in shortness of breath as measured 
by the Geriatric SOBQ.  The median score of the Geriatric SOBQ decreased from 
baseline (Mdn = 34.2) to post-TAVR (Mdn = 16.0), z = -3.01, p = .003, with a large 
effect size (r = .71).  
Table 8 





 M  SD  Mdn  M   SD  Mdn     n z p 
KCCQ 
Overall Sum 51.5 21.1 49.8 82.2 13.4 85.7 16 -3.36 .001 
Physical Lim 51.2 26.0 56.3 70.8 25.6 75.0 16 -2.13 .033 
Symptom Stab 47.1 12.1 50.0 50.0 8.8 50.0 17 -.82 .414 
Symptom Freq 58.7 26.4 60.4 78.6 18.1 75.0 17 -2.51 .012 
Symptom Brdn 53.5 23.8 50.0 85.3 15.4 83.3 17 -3.36 .001 
Total Symptom 56.1 23.7 56.3 81.9 15.9 79.2 17 -3.24 .001 
Self-efficacy 89.0 13.9 100.0 91.9 22.5 100.0 17 -1.03 .303 
Quality of Life 48.1 22.1 41.8 89.2 15.3 91.8 17 -3.52 <.001 
Social Limitation 44.2 27.4 41.8 81.1 22.2 87.5 17 -3.30 .001 
Clinical Summ 54.3 22.9 57.4 76.6 16.7 76.1 16 -2.84 .005 
SF-12 
PCS 29.1 8.8 27.9 40.0 9.6 40.3 17 -2.84 .004 
MCS 56.3 11.1 58.8 57.3 6.6 58.8 17 -.355 .723 
HADS Depression 5.8 2.5 6.0 4.7 4.2 3.0 18 -1.48 .139 
HADS Anxiety 3.8 2.7 4.0 2.0 2.0 1.5 18 -2.47 .014 
Geriatric SOBQ 35.1 21.4 34.2 16.4 14.3 16.0 18 -3.01 .003 
Physical Activity 4.5 3.7 3.0 6.8 4.8 8.0 17 -1.62 .104 
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Comparisons of QOL Improvement Based on Demographics 
As there were some statistically significant baseline differences in scores based 
on age and sex, comparisons were examined on both those demographic 
characteristics and changes in QOL. There were no significant differences identified 
based on either age or sex (Tables 9 and 10).     
Table 9 
Age Comparisons in QOL Improvement Post-TAVR 
Age 
Measure < 80 80 + 
    M     Mdn    N     M     Mdn    N 
Change in KCCQ 
Overall Summary 37.0 48.4 5 31.0 30.8 10 
Change in SF-12 
PCS  15.2 12.8 6 8.5 8.1 11 
Change in SF-12 
MCS 1.8 4.7 6 2.2 1.6 11 
Table 10 
Sex Comparisons in QOL Improvement Post-TAVR 
Sex 
Measure Men Women 
  M   Mdn   N    M    Mdn     N 
Change in KCCQ 
Overall Summary 40.05 42.55 8 24.9 20.1 7 
Change in SF-12 
PCS  13.4 13.1 10 7.3 8.1 7 
Change in SF-12 
MCS -.32 1.8 10 5.5 7.3 7 
Comparisons of QOL Improvement Based on Anxiety/Depression 
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Clinical levels of both anxiety and depression have been associated with poor 
health outcomes. Because of the small sample size, a new variable was created called 
“Anxious and/or Depressed” which included participants who had levels of either anxiety 
or depression that were at clinical cutoff at baseline. Comparisons were made to 
determine the level of improvement of the anxious/depressed group compared to 
participants who were neither anxious or depressed (Table 11). A Mann-Whitney U test 
revealed a significant difference in improvement in the SF-12 MCS of participants who 
were anxious and/or depressed at baseline (Mdn = 7.3, n = 5) versus those who were 
not (Mdn = -1.8, n = 10), U = 8.0, z = -2.637, p = .008, r = .68). Higher scores indicate 
greater improvement in MCS. There were no significant differences on either the KCCQ 
or the SF-12 PCS (Table 11). 
Table 11 
Anxious and/or Depressed Comparisons in QOL Improvement 
Sex 
Measure Anxious/Depressed Other 
  M   Mdn   N    M    Mdn     N 
Change in KCCQ 
Overall Summary 38.2 49.4 5 30.4 30.8 10 
Change in SF-12 
PCS  9.9 8.8 7 11.6 9.3 10 
Change in SF-12 
MCS* 8.0 7.3 7 -2.1 -1.8 10 
p < .01 (2-tailed) 
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Correlations Between Baseline Scores and Post-op QOL Increases 
 Correlations between baseline scores and changes in QOL post-TAVR were 
investigated using Spearman Rho to identify possible predictors of improvement in QOL 
(Table 12). The change in KCCQ score for one patient was removed from consideration 
because the baseline score was so high (97.9) there could only be minimal 
improvement. 
Table 12. 










KCCQ     
Overall Summary Score -.811** -.606* -.550* 
Physical Limitations -.690** -.434 -.446 
Symptom Stability -.271 -.071 .003 
Symptom Frequency* -.538* -.466 -.423 
Symptom Burden -.645** -.535* -.465 
Total Symptom -.584* -.529* -.431 
Self-efficacy .647** .385 -.030 
Quality of Life -.635* -.406 -.563* 
Social Limitation -.744** -.466 -.354 
Clinical Summary -.751** -.552* -.485 
SF-12     
Physical Component Score -.582* -.522* -.538* 
Mental Component Score -.086 -.100 -.690** 
HADS Depression .308 .062 .471 
HADS Anxiety -.320 .009 .320 
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Geriatric SOBQ .620* .442 .402 
SWL -.357 -.690* -.857** 
PHE .287 .140 -.192 
Physical Activity -.625* -.485 -.616* 
Med Adherence .253 .240 .216 
*p < .05 (2-tailed ), **p < .01 (2-tailed)
	  CHAPTER V: DISCUSSION 
The current study is the first to examine the inter-relationship between 
psychological functioning and QOL in TAVR patients in US centers.  The primary 
findings of this study included: 1) TAVR leads to an improvement of QOL, reduction in 
dyspnea, and reduction in symptoms of anxiety, 2) TAVR patients who demonstrated 
the greatest gains in QOL were those who reported the lowest levels of QOL prior to the 
procedure, 3) contrary to hypothesis, psychological factors such as low levels of positive 
expectations or satisfaction with life were not associated with lower gains in QOL. The 
following discussion proceeds in the order of the proposed aims of this study. 
Baseline Characteristics 
Baseline demographic characteristics of this study sample were generally quite 
similar to that reported from other TAVR studies (see Table 2). One exception was that 
the baseline mean score on the KCCQ Overall Summary Score of 54.2 was 
substantially higher than the baseline score of 39.3 reported in the PARTNER trial, a 
large US study of TAVR patients (Reynolds et al., 2012) and the only other TAVR study 
that used this measure. There are no TAVR studies with which to compare the HADS, 
SWL, PHE, dyspnea, or physical activity scores. The men in this sample reported 
somewhat better psychosocial well-being than women, as demonstrated by statistically 
significant differences on the KCCQ Symptom Burden scale, SF-12 MCS, and the 
HADS Anxiety scale. In addition, there was a trend where men reported more favorable 
QOL on the KCCQ Total Symptom scale (p = .053). Older patients in this sample 
appeared to fare somewhat better in QOL domains as demonstrated by significantly 
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better scores on the KCCQ Symptom Frequency scale, SF-12 MCS, SWL scale, and 
physical activity scale.  
Post-op Comparisons 
Examination of post-operative changes revealed significant improvement in 
disease specific QOL post-TAVR on all scales of the KCCQ that are sensitive to 
disease specific changes in QOL. The only two scales on which there were no 
significant changes were the symptom stability scale, which reports the degree to which 
symptoms of heart failure have changed over the previous two weeks, and self-efficacy, 
which is a measure of the degree to which one feels confident about how to manage 
symptoms of heart failure. It would not be expected that either of these two scales 
would be impacted by TAVR. An improvement of 5, 10, and 20 points on any subscale 
or the overall summary score represents a small, moderate, and large change 
respectively (Reynolds et al., 2012). In this sample, the mean change for each subscale 
ranged from 19.6 (Physical Limitation) to 41.1 (QOL). The mean Overall Summary 
score improved from 51.5 to 82.2 and the post-op score corresponds with NYHA  
Class I, the least severe of the four functional classes of heart failure. Collectively, these 
results suggest that the TAVR patients in this study reported significant disease specific 
QOL benefit from the procedure and highlights the value of the procedure for these 
selected patients. 
An improvement in the SF-12 PCS was similar to results from other trials as well. 
As previously noted, a change of 2.5 points is considered clinically significant on the SF-
12, and the mean change in this sample was 10.9 points. The mean SF-12 MCS 
demonstrated little change, improving from 56.3 to 57.3. This negligible improvement is 
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much smaller than in most previous studies. This may be due, in part, to the high 
baseline MCS of this sample relative to other samples that generally had baseline 
scores at least 10 points lower than the current sample. In addition, it appears 
reasonable that the benefits of TAVR would only have an ancillary effect on MCS. Of 
note, the two largest TAVR studies to date found that TAVR patients demonstrated no 
gains or only small improvements in MCS scores (Krane et al. 2012; Reynolds et al. 
2012) at similar time points post-TAVR. Again, our results suggest that TAVR patients 
benefitted significantly in generic physical QOL but experienced only limited mental 
QOL benefit.  
Consistent with these results were significant improvements in dyspnea, one of 
the most common symptoms of heart failure. Mean scores on the Geriatric SOBQ were 
cut by more than half and indicated dramatic symptomatic improvement. While the 
mean physical activity score improved, it did not reach statistical significance. Anxiety 
as measured by the HADS improved significantly as well. The reduction in symptoms of 
anxiety, while not expected, is not surprising, as some symptoms of anxiety also 
correlate with symptoms of heart failure that might be expected to improve with gains in 
cardiac health. Also, since patients completed their baseline survey usually within days 
of their TAVR, it is possible that anxiety from both their pre-op cardiac health and their 
pending procedure may have both been reflected in somewhat elevated anxiety scores. 
Considered together, the benefits of TAVR on disease-specific and physical QOL 
in this sample are striking, are consistent with other studies, and add to the growing 
literature demonstrating gains in these important areas. In addition, improvement in 
dyspnea, a problematic symptom common in patients considered for TAVR, but not 
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previously examined with a measure specific to this symptom, also demonstrated 
substantial improvement. Reduced anxiety was reported as yet, another benefit post-
TAVR. These data add to the literature by providing new detail about the psychological 
and physical experience of patients considering TAVR, and the resultant decline in 
anxiety-related symptoms post-TAVR that they might experience.  
Demographic Differences in Baseline and Post-op Scores 
The benefits of TAVR were not statistically different between the younger and 
older age groups, or between men and women in this study. There are few studies 
reporting comparisons based on these demographic characteristics post-TAVR. 
Reynolds et al. (2011) found no significant differences in improvement in QOL at 6 or 12 
months based on either age or gender. Krane et al. (2012) found that while female 
gender was associated with less improvement in QOL at 3 months, there was no 
statistically significant difference at 12 months. Fairbairn et al. (2012) reported that men 
reported greater improvement in QOL at 12 months. There were no age differences in 
changes in QOL found by Fairbairn et al., however. The results of the current study 
combined with the mixed results from past studies, suggest that age and sex likely have 
minimal, if any, association with outcome.  
Predicting Outcomes 
 As increasing numbers of TAVR studies have been published and the benefits of 
TAVR have become more well-defined and accepted, the future of TAVR as a viable 
procedure for valve disease has become more certain. Accompanying the growth of 
scientific knowledge has been a greater quest to gain an understanding of predictors of 
outcomes. There have been a few studies seeking to identify predictors of mortality or 
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medical complications such as stroke or kidney dysfunction (Gilard et al., 2012; Seiffert 
et al., 2013; Moat et al., 2011; Rodés-Cabau et al., 2012) but until recently, none have
used QOL as an endpoint. Arnold et al. (2014) in using results from the PARTNER trial, 
published findings examining possible predictors of outcomes in TAVR patients that 
used both mortality and QOL as endpoints. As they noted, “…the optimal definition for a 
poor outcome after TAVR should reflect a failure to achieve the goals of the intervention 
and therefore must include both a mortality and a QoL component” (p. 2687). With a 
large sample size (N = 2137), they were able to use a split-sample design and a 
multivariable logistic regression model to examine a range of demographic, disease 
specific, physical, and QOL variables. They found that the most important predictors of 
poor outcomes were poor functional capacity (as assessed by the distance walked on 
the 6 Minute Walk Test), lower mean aortic valve gradients, oxygen-dependent lung 
disease, renal dysfunction, poorer baseline cognitive function, lower BMI, and worse 
QOL at baseline. While such predictive models cannot guarantee results they do 
provide important information to patients, family members, and health-care providers to 
increase understanding of the likelihood of benefit versus the risks involved.  
Using improvement in QOL as an outcome, our results were a modest attempt at 
providing greater understanding of a diverse set of variables that are associated with 
patient outcome in TAVR. Generally, the results indicated that patients in this sample 
who reported the worst biopsychosocial health at baseline demonstrated the greatest 
gains. For example, patients who had the lowest baseline KCCQ Overall Summary 
scores and/or lowest SF-12 PCS demonstrated the greatest gains post-op on the KCCQ 
Overall Summary score, the SF-12 PCS, and the SF-12 MCS. Similar correlations were 
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noted for scores on the Geriatric SOBQ, Satisfaction with Life scale, and the physical 
activity score such that worse scores in these areas were correlated with greater 
improvement in QOL. Patients who completed the KCCQ at both pre-op and post-op 
and who had baseline scores < 50 on their Overall Summary demonstrated gains 
ranging from 12.4 to 69.8 with a mean improvement of 47.4. To summarize, patients 
who present with particularly low self-reports of QOL, including low satisfaction with life, 
and/or who experience problematic dypsnea, and/or low levels of physical activity are 
likely to experience large and meaningful gains in QOL. Therefore, the substantial QOL 
benefit that patients eligible for TAVR may likely experience is important to highlight and 
should be part of the consideration process.  
Psychological Distress and TAVR Outcomes 
Higher scores on the HADS for either anxiety or depression were not associated 
with lack of improvement as measured by QOL measures. At baseline, eleven patients 
met the cut-off for mild depression while seven met the cut-off for mild anxiety. Of those, 
only five patients meeting cut-off for depression and two meeting cut-off for anxiety 
completed the post-op survey, precluding meaningful between groups analyses for 
these factors individually. Instead, one group who met cutoff for anxiety and/or 
depression was created and compared to the remaining participants on improvement in 
QOL. Anxiety or depression was not associated with worse outcomes, and in fact, there 
was statistically greater improvement in MCS among participants with anxiety and/or 
depression. This suggests that the physiological benefits of TAVR may have been of  
such magnitude that they were recognized even by those experiencing clinical levels of 
psychological distress during the timeframe of the procedure. 
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Medication Adherence 
Non-adherence to medication protocol has been defined as taking medications 
as prescribed only 75% of the time or less (Gehi et al., 2007). Estimated average 
adherence rates to medication instructions in cardiac patients has been found to be 
between 51% to 79%, depending on the number of daily doses (Horwitz et al., 1990).
The patients in this study demonstrated far higher medication adherence than might be 
expected, as 100% of participants self-reported taking their medications “nearly every 
day” for the previous month. Such strong self-reported adherence to medications may 
be a reflection of both patient specific and situation specific characteristics. For 
example, excellent adherence may highlight the patient understanding of the severity of 
their condition. Alternatively, there may have been a high proportion who lived in 
assisted living situations in which daily support for medication management is the norm. 
As medication adherence has not been studied in TAVR patients before, it is unknown if 
these results mirror that of TAVR patients in general or represent a positive report bias.  
Will to Live 
Responses to the Will to Live measure proved to be generally uniform in our 
sample. Of all the study measures, this measure anecdotally drew the greatest vocal 
response from participants who would often respond with something like, “What kind of 
question is that? Who wouldn’t circle a 10 on that?”   For example, 29 of 34 participants 
rated their will to live at baseline as a “10” with 10 being the greatest will to live possible. 
At post-op, 16 of 18 respondents rated their will to live as a 10 with the other two 
respondents recording responses of 8 and 9.7. Of note, however, the one mortality 
identified among participants completing the first survey responded that his will to live 
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was a 7.5, the second lowest response received among our sample. While it is possible 
that with a larger sample this measure may be shown to have predictive value 
concerning outcome, our preliminary results did not indicate that and the measure 
appears to have limited value from our experience. It is also possible that the way in 
which we assessed this item, with a single VAS, may not be sensitive enough to 
adequately capture this construct and again may be subject to a positive response bias 
in these patients. 
Positive Health Expectations 
The role of positive health expectations on outcomes had not previously been 
studied in this population. While positive expectations about the future have been found 
to be associated with better mental and physical health by a number of studies 
(Peterson & Bossio, 2001; Scheier et al., 1989; Taylor & Brown, 1988) including in 
cardiac patients (Leedham et al., 1995; Sears et al., 2004) that was not the case in our 
sample. This construct was not significantly correlated with baseline QOL in our study. It 
is possible, since our survey was administered after patients had decided to proceed 
with the TAVR procedure, that they had essentially become somewhat confident or 
hopeful that it would be of benefit. Their scores on the PHE scale at baseline might 
therefore be a reflection of this thought process more than a reflection of their 
perception of QOL. Positive expectations were not significantly associated with 
improvement in QOL post-TAVR either. As with psychological distress, this suggests  
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that the physiological benefits of TAVR may have been of such magnitude that they 
were recognized by participants regardless of prior level of expectation.  
Geriatric SOBQ as an Assessment Tool  
As previously described, many participants chose not to answer several 
questions included in the University of California, San Diego Shortness of Breath 
Questionnaire (SOBQ) that queried the degree of breathlessness experienced while 
conducting a variety of activities. If administered in person, they would often respond to 
the study assistant that they had either not done the activity any time recently, or  
currently engaged in them too infrequently to feel comfortable assessing (e.g., washing 
a car, mowing a lawn). This choice was made by participants in spite of instructions  
stating that “if the activity is one which you do not perform, please give your best 
estimate of breathlessness.”  Missing data on this questionnaire was common across 
both study sites. Therefore, questions that were answered by fewer than 75% of 
participants (in the current study questions 14 and 17-21) were removed from 
consideration in this analysis. This revised tool entitled “Geriatric SOBQ” still provided a 
detailed assessment of a common symptom of valve disease and also had high internal 
consistency. We suggest that this shorter tool is more appropriate for patient 
populations marked by greatly reduced physical health and may be a more viable option 
for future research with similar groups. This abbreviated measure will reduce irrelevant 
questions, ease patient burden, and likely provide data that is as accurate and possibly 
more accurate than the complete SOBQ by refraining from inquiring about activities in 
which participants cannot engage due to their significant physical limitations.  
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Of note, there was a very strong negative correlation between the baseline 
Geriatric SOBQ and the baseline KCCQ Overall Summary Score (r = -. 87, n = 34, p < 
.001) with high levels of dyspnea associated with low levels of cardiac-health related 
QOL. These results suggest that dyspnea, as measured by the Geriatric SOBQ, may 
significantly and substantially impact QOL for cardiac patients as assessed by the 
KCCQ. This also suggests that reduced dyspnea should be an important endpoint for 
TAVR. 
Limitations of the Current Study 
There are several important limitations to this study that affect the ability to 
generalize findings to the TAVR population as a whole. The small sample size is a 
foremost limitation and inferences derived from these results must be viewed with 
caution. In addition, there were a high number of participants who were lost to follow-up 
increasing the possibility of selection bias. While comparisons conducted of baseline 
measures of patients lost to follow up and those completing the study found no 
significant differences, the post-op results for patients lost to follow up, of course, 
remain unknown. The study sample was quite racially homogeneous, a result that was 
surprising to the investigators considering the racial mix within the general population at 
the East Carolina site particularly. All but two participants identified as Caucasian and 
therefore, generalizing these findings to other racial groups must be done with extreme 
caution.  
Limitations of the Study Design 
The study was designed recognizing the limited number of prospective TAVR 
patients available in the geographic area in which it was conducted. For that reason, 
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statistical analyses were relatively simplistic as did comparisons between groups. Thus, 
results may be considered most valuable by providing direction for future research. 
Another limitation is the reliance on self-report and possible response bias. The 
inclusion of more biomedical data would add to the validity of participant self-report on 
physical well-being, for example.  
Future Implications and Aims 
Future studies are necessary to continue to increase the understanding of 
biopsychosocial predictors of outcomes in the population of those qualifying for TAVR. 
Psychological factors that have predictive validity are subject to change and the use of 
interventions to address these factors may lead to improved outcomes. While this small 
study did not identify such factors, that should not imply that such factors do not exist. A 
broad and robust literature associated with psychosocial factors in cardiology exists with 
decades of significant relationships (Rozanski, et al., 2005).  Research comparing 
samples of TAVR patients with poor outcomes with those who experienced desirable 
outcomes are needed to increase understanding of predictive factors. TAVR will likely 
continue to expand to increasingly “healthier” groups where psychological factors and 
motivation are more likely to exert a detectable influence over and above gross physical 
dysfunction. Arnold et al. (2014) is a recent example of research examining differences 
between large patient groups based on outcomes. Unfortunately, they did not include 
psychological factors other than QOL in their design. Frailty has been implicated as a 
likely predictor of outcomes in TAVR patients (Green et al., 2012; Stortecky et al., 
2012). While traditional models of frailty have only included physical factors, future 
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research should investigate the way in which psychologic factors may also be 
considered as predictors in a broader, biopsychosocial model of frailty.  
Conclusion 
The main findings of this study suggest that TAVR leads to an improvement of 
QOL, reduction in dyspnea, and reduction in symptoms of anxiety. TAVR patients who 
demonstrate the greatest gains in QOL were those who reported the lowest levels of 
QOL prior to the procedure. Contrary to hypothesis, there was no significant association 
between baseline levels of positive expectations, satisfaction with life, or psychological 
distress, with post-op QOL improvement. These findings suggest that the physiological 
benefits of TAVR are of such magnitude that they are experienced by patients 
regardless of less than ideal psychosocial beliefs or distress. In addition, it is reasonable 
for patients to expect meaningful gains in QOL post-TAVR and, in fact, those patients 
who report the worst biopsychosocial health at baseline may likely experience the most 
substantial QOL improvements. However, these findings are preliminary and studies 
with larger sample sizes are necessary to draw more definitive conclusions. 
Understanding a biopsychosocial model for TAVR will likely provide comprehensive 
strategies to optimize clinical outcomes for TAVR patients as the procedure continues to 
expand to “healthier” populations.  
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  APPENDIX B – GLOSSARY OF MEASURES 
Euroqol5D (EQ-5D) – The EQ-5D is a preference/utility-based measure that describes 
five dimensions: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression (Herdman et al., 2011). Participants are asked to select one option 
that best describes their health concerning that dimension from three or five different 
possibilities depending on version. The question concerning anxiety/depression asks 
patient’s to select one of three responses:  I am not anxious or depressed; I am 
moderately anxious or depressed; I am extremely anxious or depressed. They also rate 
their overall health on a visual analogue scale (VAS) from 0 to 100. The EQ 5D 
identifies 243 health states. The EQ 5D has been used in over 500 studies and is used 
in a variety of ways including monitoring patient health status, assessing health 
condition severity, evaluating the effectiveness of health procedures and medications, 
and in economic studies designed to determine resource allocation (Fairbairn et al., 
2012; Rabin & Charro, 2001).  
Hospital Anxiety and Depression Scale (HADS) - The HADS is a 14-item measure 
that assesses depression and anxiety and is used primarily in hospital settings 
(Zigmond & Snaith, 1983). All somatic symptoms related to depression and anxiety are 
excluded from this measure in order to account for the likely experience of such 
symptoms from known or expected physiological problems in this population. Seven 
items on the scale  assess depression and the other seven items assess anxiety. Each 
item is scored from 0-3 and an established clinical cutoff of 8. A review by Bjelland, et 
al., (2002) identified over 700 studies that used the HADS. They found that most factor 
analyses confirmed the two-factor solution in accordance with the subscales of anxiety 
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(HADS-A) and depression (HADS-D) with Cronbach's alphas for HADS-A varying from 
.68 to .93 (mean .83) and for HADS-D from .67 to .90 (mean .82). 
Kansas City Cardiomyopathy Scale (KCCQ) – The KCCQ is a 23-item measure  
commonly used to evaluate the health status of heart failure patients (Creber et al., 
2012). The five domains addressed by the KCCQ are:  symptoms, physical limitation, 
social limitation, self-efficacy, and quality of life (Green et al., 2000). The individual scale 
scores may be combined into an overall summary scale with scores from 0 to 100; 
higher scores are indicative of fewer symptoms and higher QOL.  The KCCQ summary 
score has been found to correlate with NYHA functional class as follows: class I is 
roughly equal to KCCQ summary score of 75 to 100; class II, to a score of 60 to 74; 
class III, to a score of 45 to 59; and class IV, to a score of 0 to 44 (Spertus et al., 2005). 
Arnold et al. (2013) evaluated the psychometric properties of the KCCQ in patients with 
severe aortic stenosis and found good construct validity when comparing each domain 
of the KCCQ against a reference measure. In the study by Creber et al., the Cronbach’s 
alpha was 0.92 indicating excellent internal consistency. 
Logistic EuroSCORE (EuroSCORE) – The EuroSCORE is used to predict outcomes 
of patients undergoing cardiac surgery. It was developed in 1999 and considers 17 
parameters grouped into three areas: patient related risk factors (e.g., age, history of 
cardiac surgery); cardiac factors (e.g., reduced LVEF, recent myocardial infarction); and 
operation related factors (e.g., emergency operation, other than isolated coronary 
surgery) (Nashef et al., 1999). Each of these three areas has a different weight in the 
scoring algorithm. Studies have criticized the EuroSCORE for overestimating mortality 
by about twice as much as actual outcome (Siregar et al., 2012).  
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Minnesota Living with Heart Failure Questionnaire (MLHFQ) - The MLHFQ is a 21-
item structured questionnaire that measures patient perceptions about the effects of 
symptoms, functional limitations and psychological distress of an individual's QOL 
(Goncalves et al., 2013). Respondents rate the degree that each heart failure related 
item prevents them from living as they wanted during the previous four weeks using a 6-
point Likert Scale . Responses range from 0 (no impact/not applicable) to 5 (severe 
impact). The MLHFQ produces a total score (21 items, range: 0 to 105), physical score 
(range: 0 to 40 for 8 items) and emotional dimension score (range: 0 to 25 for 5 items), 
respectively). Lower scores indicate better HQOL and a change ≥5 points in total score 
is considered clinically meaningful. The questionnaire can be self-administered or 
applied in a 5-minute interview. The MLHFQ had been compared to the SF-36 in a 
sample of valve patients and has been found to have good psychometric properties 
(Supino et al., 2009). 
Patient Health Questionnaire-9 (PHQ-9) – The PHQ-9 is a nine-item measure of 
depressive symptoms that is commonly used among patients in medical settings  
(Kroenke, Spitzer & Williams, 2001). There are four possible responses for each item 
and total scores range from 0 to 27 with higher scores indicating higher levels of 
depression. Reliability and construct validity has also been found to be excellent. The 
PHQ-9 has demonstrated sensitivity for major depression of 88% compared with the 
mental health professional (MHP) interview. Internal consistency has been found to be 
good with Cronbach’s alpha between 0.86 and 0.89.  
Positive Health Expectations Scale (PHE) – The PHE assesses patient beliefs about 
the efficacy of their treatment and their future outlook (Leedham et al., 1995). The scale 
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was first used with heart transplant patients and demonstrated good convergent validity 
with QOL scores, divergent validity with mood disturbances scores, and predictive 
validity with physical health measures. Sears et al. (2004) used this measure to assess 
PHE in ICD patients and modified it with an added question assessing motivation for 
ICD implantation. The current study has similarly modified the PHE with a question 
assessing motivation for valve surgery. Respondents rate their health expectations on a 
7-point Likert scale. There are eight questions and possible scores range from 8 to 56
with higher scores indicating a more positive outlook. Cronbach’s alpha was 0.81 and 
0.88 in the Leedham et al. and Sears et al. studies respectively, indicating good internal 
consistency.  
Short Form 36 Health Survey (SF-36) – The SF-36 survey was developed in 1992 and 
was constructed to provide a comprehensive yet brief, psychometrically sound measure 
of health status (Ware & Sherbourne, 1992). The SF-36 assesses eight health 
concepts:  limitations in physical activities because of health problems; 2) limitations in 
social activities because of physical or emotional problems; 3) limitations in usual role 
activities because of physical health problems; 4) bodily pain; 5) general mental health 
(psychological distress and well-being); 6) limitations in usual role activities because of 
emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. 
It may be self-administered or administered by a trained interviewer in person or by 
phone in about five minutes. Dexter, Stump, Tierney & Wolinsky (1996) evaluated the 
psychometric properties of the SF-36 among 1053 older adults (>50 with severe 
underlying disease or >75) and found these eight factors explained 65% of the item 
variance with most items loading on the appropriate factors. Exploratory factor analysis 
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also found one single underlying health factor as well as a two factor solution for the 
components of mental and physical health. Falcoz, Chocron, Mercier, Puyraveau, and 
Etievent (2002) evaluated the SF-36 in cardiac patients and found the psychometric 
properties to be generally good.   
Short Form12 Health Survey (SF-12) – The SF-12v2 is a 12-item revision of the SF-36 
(Ware et al., 1996) and will provide one general health measure of QOL for this study. 
The SF-12 maintains 90% of the variance of the mental and physical health scales of 
the SF-36, although it has less accurate reproduction of the eight scales of the SF-36. 
Administration time is lowered from five minutes to two minutes for the SF-12. The SF-
12v2 is an updated version of the SF-12 that adjusted some of the response options. A 
recent review of the SF-12v2 using a large, adult patient population (N = 2,410) found 
that the mental and physical health scales explained over 80% of the total variances of 
the SF-36v2 (Lam et al., 2013). The SF-12v2 is scored by computer and provides a t-
score based on a representative US population sample. Recently evaluated Cronbach’s 
alpha on the physical component scale has been found to range from 0.81 - 0.90 (mean 
= 0.87) in various population groups (DeSmedt et al., 2013). Cronbach’s alpha on the 
mental component scale ranged from 0.74 – 0.89 (mean = 0.84). The mean Cronbach’s 
alpha values for this review indicate good internal consistency for both scales.  
Short Form 6D (SF 6D) – The SF 6D calculates the measure of disease burden in 
terms of quality-adjusted life years (QALYs) from participant responses to the SF-36 or 
SF-12 (Phillips & Thompson, 2009). QALYs measure this burden by considering the 
quality and quantity of life gained by medical interventions and comparing that to the 
financial cost of the intervention. One QALY is equivalent to one perfect year of life. The 
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SF 6D reduces the dimensions of the SF-36 to six dimensions: physical functioning, role 
limitation, social functioning, pain, mental health, and vitality. The SF 6D identifies 
18000 health states. (Querecioli et al., 2009). Scores range from 0 (death) to 1 (full 
health). 
Society of Thoracic Surgeon risk score (STS) – The STS predicts risk of mortality in 
patients considered for cardiac surgery including TAVR. STS is calculated using an 
algorithm  considering over 40 clinical parameters including patient demographics and 
various risk factors such as height/weight, diabetes, renal failure, hypertension, chronic 
lung disease, peripheral arterial disease, cerebrovascular disease, previous cardiac 
interventions, preoperative cardiac status, ejection fraction, and aortic stenosis (Ad et 
al., 2007).  STS score is often used to identify high-risk patients considered for TAVR 
although it has been found to have limited success in predicting future mortality (Piazza 
et al., 2010). 
The University of California, San Diego Shortness of Breath Questionnaire 
(SOBQ) – The SOBQ is a self-report questionnaire in which patients indicate the 
severity of dyspnea experienced during 21 activities of daily living that vary in rate of 
exertion (Eakin et al., 1998). Ratings for each item are on a 6-point scale (e.g., 0 = Not 
at all, 4 = Severely, 5 = Maximally or unable to do because of breathlessness). An 
additional three questions inquire about limitations due to shortness of breath, fears 
about overexertion, and fear of shortness of breath. Maximum score is 120 and a 
change of 5 points is considered clinically significant. (Ries, 2005). Reliability has been 
found to be superior to other measures of dyspnea including the Baseline Dyspnea 
Index (BDI), American Thoracic Society Dyspnea Scale and the Oxygen Cost Diagram 
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(Eakin et al., 1998). Validity has been found to be good after examination of variables 
with which is it believed to be related such as exercise tolerance, health-related QOL, 
lung function, and depression. The study by Eaken et al. found a Cronbach’s alpha 
value of 0.96 indicating excellent internal consistency.  
Will-to-live: The last item in the survey will ask participants to rate their will-to-live on a 
single-item VAS with anchors of “no will to live” and “absolute will to live”. This scale has 
been used in one other study and had high correlation with depression, anxiety, desire 
for death, burden to others, and hopelessness (Chochinov et al., 2005). However, its 
psychometric properties have not been evaluated. There are no published scales of 
measures of will-to-live for which psychometric properties have been evaluated.  
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